CONFIDENTIAL  Protocol BL010 version 1.0 
 
 1 Title Page 
Protocol Title: A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the 
Feasibility  of Home Instillation of UGN -102 for Treatment of Patients with 
Low-Grade (LG) Non -Muscle -Invasive Bladder Cancer (NMIBC) at 
Intermediate Risk (IR) of Recurrence  
 
Protocol Number: BL0 10 
Compound: UGN- 102 (mitomycin) for intravesical solution  
Study Phase:  3b 
Sponsor Name: [CONTACT_113566].  
Legal Registered Address:  
9 Ha’Ta’asiya Street  
Ra’anana, Israel 4365405 
 
Regulatory Agency Identifier Number(s):  
IND [ADDRESS_126609] Information  
 
Medical Director/Medical Monitor  
, MD, UroGen Pharma 
 
 
 
Study Ma
nager  
, UroGen Pharma 
 
 Quality A
ssurance  
, UroGen Pharma  
 
 
[EMAIL_2242]   
Study Logistics  
, UroGen Pharma 
 

CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126610] of In -text Appendices ...............................................................................................................6  
Statement of Compliance  ..............................................................................................................7  
1. Protocol Summary ..........................................................................................................8  
1.1. Synopsis ............................................................................................................................8  
1.2. Schema  ............................................................................................................................11  
1.3. Schedule of Activities  .....................................................................................................12  
Abbreviations  ...............................................................................................................................14  
2. Introduction ...................................................................................................................16  
2.1. Study Rationale ...............................................................................................................17  
2.2. Benefit -Risk Assessment  ................................................................................................18  
2.2.1.  Risk Assessment  .............................................................................................................18  
2.2.2.  Benefit Assessment  .........................................................................................................19  
2.2.3.  Overall Benefit -Risk Conclusion ....................................................................................19  
3. Objectives and Endpoints  ............................................................................................20  
4. Study Design ..................................................................................................................21  
4.1. Overall Design  ................................................................................................................21  
4.2. Scientific Rationale for Study Design  ............................................................................22  
4.3. Justification for Dose  ......................................................................................................23  
4.4. End-of-Study Definition  .................................................................................................23  
5. Study Population  ...........................................................................................................23  
5.1. Inclusion Criteria  ............................................................................................................23  
5.2. Exclusion Criteria  ...........................................................................................................24  
5.3. Lifestyle Considerations  .................................................................................................25  
5.4. Screen Failures  ................................................................................................................25  
5.5. Strategies for Recruitment and Retention  .......................................................................25  
5.6. Criteria for Temporarily Delaying Administration of Study 
Treatment  ........................................................................................................................25  
6. Qualified Health Care Personnel .................................................................................26  
6.1. Clinical Nurse Educators  ................................................................................................26  
6.2. Home Health Professionals  .............................................................................................26  
7. Study Treatment  ...........................................................................................................27  
7.1. Study Treatment Administered  .......................................................................................27  
7.1.1.  Study Treatment Description  ..........................................................................................27  
7.1.2.  Preparation and Administration Ancillary Supplies .......................................................28  
7.1.3.  Administration and Dosing .............................................................................................28  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 4 7.2. UGN-102 Single Dose Carton /Handling/Storage/Accountability .................................[ADDRESS_126611]/Concomitant and Prohibited Therapy .....................................................................32  
7.7.1.  Rescue Medicine  .............................................................................................................32  
8. Discontinuation of Study Treatment and Patient Discontinuation/Withdrawal........................................................................................33
 
8.1. Discontinuation of Study Treatment ...............................................................................33  
8.1.1.  Temporary Withholding of Study Treatment  .................................................................33  
8.1.2.  Rechallenge  .....................................................................................................................33  
8.1.3.  Withdrawal of Consent for Home Instillation of Study Treatment  ................................33  
8.2. Patient Discontinuation/Withdrawal from the Study  ......................................................[ADDRESS_126612] to Follow-up............................................................................................................34  
9. Study Assessments and Procedures .............................................................................35  
9.1. Study Assessments and Procedures by [CONTACT_4838]  ..................................................................35  
9.2. Efficacy Assessments  .....................................................................................................35  
9.2.1.  Measurements for Evaluation of Response at 3 -month Visit  .........................................35  
9.2.2.  Evaluation of Treatment Response at 3 -month Visit (Disease 
Assessment)  ....................................................................................................................35  
9.2.3.  Pathological Evaluation ..................................................................................................36  
9.3. Safety Assessments  .........................................................................................................36  
9.3.1.  Physical Examinations  ....................................................................................................37  
9.3.2.  Vital Signs  .......................................................................................................................37  
9.3.3.  Clinical Safety Laboratory Assessments  ........................................................................37  
9.3.4.  Urinalysis  ........................................................................................................................39  
9.3.5.  Pregnancy Testing ...........................................................................................................39  
9.4. AEs, SAEs, and Other Safety Reporting ........................................................................39  
9.4.1.  AEs and SAEs  .................................................................................................................40  
9.4.2.  Time Period and Frequency for Collecting AE and SAE Information  .....................................................................................................................43
 
9.4.3.  Method of Detecting AEs and SAEs ..............................................................................44  
9.4.4.  Follow-up of AEs and SAEs ...........................................................................................44  
9.4.5.  Regulatory Reporting Requirements for SAEs ...............................................................44  
9.4.6.  Serious Adverse Event Reporting ...................................................................................45  
9.4.7.  Pregnancy ........................................................................................................................46  
9.4.8.  Disease- Related Events and/or Disease- Related Outcomes Not 
Qualifying as AEs  or SAEs  .............................................................................................46  
9.4.9.  AESIs  ..............................................................................................................................46  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 5 9.5. Pharmacokinetics  ............................................................................................................46  
9.6. Genetics and/or Pharmacogenomics  ...............................................................................46  
9.7. Biomarkers  ......................................................................................................................47  
9.8. Immunogenicity Assessments .........................................................................................47  
9.9. Home Instillation Feasibility Questionnaires  .................................................................47  
10. Statistical Considerations  .............................................................................................48  
10.1.  Statistical Hypotheses  .....................................................................................................48  
10.2.  Sample Size Determination  ............................................................................................48  
10.3.  Analysis Set  ....................................................................................................................48  
10.4.  Statistical Analyses  .........................................................................................................48  
10.4.1.  General Considerations  ...................................................................................................48  
10.4.2.  Primary Endpoint(s)  ........................................................................................................48  
10.4.3.  Secondary Efficacy Endpoint(s) .....................................................................................[ADDRESS_126613] of In -text Appendices 
Appendix A.  Patient Questionnaire  ............................................................................................ 61  
Appendix B.  Home Health Professional Questionnaire  ............................................................. 63  
Appendix C.  Investigator Questionnaire  .................................................................................... 64  
 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 7 Statement of Compliance  
The study will be conducted in accordance with International Council for Harmonisation  
Good Clinical Practice (ICH GCP) and the applicable [LOCATION_002] (US) Code of Federal 
Regulations (CFR). The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the Sponsor, except where necessary to 
eliminate an immediate hazard(s) to the study patients.  
The protocol, informed consent form(s), recruitment materials, and all patient materials will be 
submitted to the Institutional Review Board  (IRB)/Independent Ethics Committee  (IEC) for 
review and approval. Approval of both the protocol and the consent form must be obtained before any patient is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_1201]/IEC before the changes are implemented to the study. All changes to the consent form will 
be IRB/IEC approved; a determination will be made regarding whether a new consent needs to be 
obtained from patients who provided consent, using a previously approved consent form. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 8 1. Protocol Summary 
1.1. Synopsis  
Protocol Title: A Phase 3b, Open-Label, Single -Arm, Multicenter Study to Assess the 
Feasibility  of Home Instillation of UGN -102 for Treatment of Patients with 
Low-Grade (LG) Non -Muscle -Invasive Bladder Cancer (NMIBC) at 
Intermediate Risk (IR) of Recurrence  
Overall Design:  This  Phase 3b, open-label, single- arm, multicenter study is designed to assess 
the feasibility of home instillation of UGN -102 (mitomycin) for intravesical solution  in 
approximately 10 patients with  low- grade  (LG) intermediate risk  (IR) non- muscle-invasive 
bladder cancer  (NMIBC). 
The primary objective of this study is to evaluate the feasibility of home instillation of UGN -102 
as an alternative to instillation in a clinical  setting. Feasibility will be assessed by [CONTACT_113509], rate of discontinuation from at home study treatment , and feedback from 
patient s, home health professionals, and investigators via  standardized  questionnaires. The 
secondary objective of this study is to evaluate the efficacy of UGN -102 for the treatment of 
LG IR NMIBC following home instillation.  Efficacy will be assessed at the 3- month Visit 
([ADDRESS_126614] instillation of UGN -102) by [CONTACT_113510] (CRR) , defined as 
the proportion of patients who achieved complete response ( CR) as determined by [CONTACT_113511], 
for cause biopsy, and urine cytology. 
Patients who provide informed consent will undergo a Screening Visit to determine eligibility. 
Approximately 10 patients ≥  [ADDRESS_126615] instillation 
will be performed at the investigative site and subsequent instillations will be performed at the 
patient’s home by a properly  trained and qualified home health professional. 
End-of-study  (EOS)  is defined as the last patient last visit (LPLV) . The EOS will be declared 
after all patients have completed the 3-month Visit (7  weeks ± 1 week  after the final instillation 
of UGN-102).  
Following the 3- month Visit, all patients will exit the study and continue with standard of care 
according to their treating physician. 
Objectives and Endpoints:  
Objective  Endpoints  
Primary   
To evaluate the feasibility of home 
instillation of UGN -102 for treatment of 
patients with LG IR NMIBC  Feasibility will be assessed by [CONTACT_29657]:  
• Safety and tolerability  
o Reporting of AEs, including SAEs and AESIs  
o Standard clinical laboratory tests (hematology, 
serum chemistry, and urinalysis)  
o Physical examination and vital sign measurements  
• Rate of discontinuation from at home study treatment  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 9 Objective  Endpoints  
• Feedback from patients , home health professionals,  and 
investigators  via standardized questionnaires  
Secondary   
To evaluate the efficacy of UGN -[ADDRESS_126616] 
to complete response rate (CRR) at the 
3-month disease assessment  CRR  is defined as the proportion  of patients who achieved CR  
at the 3-month Visit ([ADDRESS_126617] instillation of 
study treatment) as determined by [CONTACT_113511], for cause biopsy, and urine cytology  
AE = adverse event; AESI = adverse event of special interest; CR = complete response; CRR = complete response  
rate; LG IR NMIBC  = low-grade intermediate risk non -muscle -invasive bladder cancer ; SAE  = serious  adverse event.  
Inclusion Criteria:   
1. Capable of giving written informed consent, which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 
2. Patient must be ≥  18 years of age at the time of signing the ICF. 
3. Patient who has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by [CONTACT_113512] 8  weeks before Screening. 
4. Has IR disease, defined as having 1  or 2 of the following: 
• presence of multiple tumors . 
• solitary tumor >  3 cm . 
• recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis at the initial Screening Visit). 
5. Negative voiding cytology for high-grade ( HG) disease within 6  weeks before Screening . 
6. Has adequate organ and bone marrow function as determined by [CONTACT_113513]:  
• Leukocytes ≥  3,000/μL (≥  3×10
9/L). 
• Absolute neutrophil count ≥  1,500/μL (≥  1.5×109/L). 
• Platelets ≥  100,000/μL (≥  100×109/L). 
• Hemoglobin ≥  9.0 g/dL. 
• Total bilirubin ≤  1.5 × upper limit of normal (ULN). 
• Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) ≤  2.5 × ULN. 
• Alkaline phosphatase (ALP) ≤  2.5 × ULN. 
• Estimated glomerular filtration rate (eGFR) ≥  30 mL/min . 
7. Has no evidence of active urinary tract infection (UTI) at the Screening  and baseline visits . 
8. Patient is willing to receive instillations of UGN -102 at home (ie, Treatment Visits  2 to 6) 
by [CONTACT_113514]. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
 10 9. Contraceptive use by [CONTACT_113515]. Women of childbearing 
potential (defined as premenopausal women who have not been sterilized), including female patients and female partners of male patients, must be willing to use [ADDRESS_126618] a low failure rate (ie, less than 1% per year) when used consistently and correctly include implants, injections, combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only hormonal), condoms with spermicide, sexual abstinence, or vasectomized partner.  
10. Has an anticipated life expectancy of at least the duration of the trial.  
Exclusion Criteria:  
1. Received Bacillus Calmette -Guérin  (BCG) treatment for urothelial carcinoma (UC) 
within previous 1 year. 
2. History of HG bladder cancer ( pap illary  or carcinoma in situ) in the past 2 years. 
3. Known allergy or sensitivity to mitomycin that in the Investigator’s opi[INVESTIGATOR_113492] . 
4. Clinically significant urethral stricture that would preclude passage of a urethral catheter. 
5. History of: 
• neurogenic bladder . 
• active urinary retention . 
• any other condition that would prohibit normal voiding. 
6. Past or current T1 UC, muscle invasive UC (ie, T2, T3, T4), metastatic UC , or concurrent 
upper tract urothelial carcinoma (UTUC). 
7. Has an underlying substance abuse or psychiatric disorder such that, in the opi[INVESTIGATOR_684], the patient would be unable to comply with the protocol. 
8. History of prior treatment with an intravesical chemotherapeutic agent in the past 2  year
 s 
except for a single dose of chemotherapy immediately after any previous transurethral 
resection of bladder tumor s (TURBT) . 
9. Has participated in a study with an investigational agent or device within 30 days of enro
llment.  
Number of Patient s: Approximately 10 patients will be enrolled and treated in this study.  
Number of Investigative  Sites: The study will be conducted at approximately 5 investigative 
sites in the US . 
Qualified Health Care Personnel: The study will be conducted by [CONTACT_113516]. Clinical n urse educators (CNEs)  will train 
pharmacy personnel on study treatment preparation and study personne l (eg, investigators  and 
home health professionals) on the UGN-102 instillation procedure. 
Treatment and Duration:  Eligible patients will be treated with 6  once- weekly  intravesical 
instillations of UGN-102 (75 mg mitomycin  in 56  mL admixture ; 1.33 mg mitomycin per 1  mL 
of admixture). Data Review Committee: None. 
CONFIDENTIAL Protocol BL010 version 1.0
11 Statistical Analyses: No formal hypothesis will be tested. The sample size of this study 
(approximately 10 patients) is based on feasibility. 
Safety data will be analyzed descriptively. Point estimates of the secondary endpoint CRR at the 
3-month Visit along with the exact 95% confidence interval (CI) will be summarized. 
The Safety Analysis S et that includes all patients  who received any dose of UGN-102 will serve 
as the primary population for the analyses of safety and efficacy data in this study.
No interim analysis will be conducted. The final analysis will be performed after all patients 
complete the end of study visit or are withdrawn from the study. 
1.2. Schema
a. One day after every home instillation (+ 1 day).

CONFIDENTIAL  Protocol BL010 version 1.0 
 
12 1.3. Schedule of Activities  
Procedures Screening 
Period a Treatment 
Visit 1 
(Baseline)  Treatment 
Visit 2  Treatment 
Visit 3  Treatment 
Visit 4  Treatment 
Visit 5  Treatment 
Visit 6  3-month Visit 
(EOS)  ET 
Planned Location Clinic  Clinic  Home  Home  Home  Home  Home  Clinic  Clinic  
Day/Week/Month D-14 to D -1 
or  
D-28 to D -1 D1/W1 D8/W2 D15/W3 D22/W4 D29/W5 D36/W6 3 months  
(7 weeks ±1 wee k 
after final 
instillation ) NA 
Window b NA D-1 
+1/+7 d  -1/+3 d  -1/+3 d  -1/+3 d  -1/+3 d  -1/+3 d  ±1 w eek NA 
Informed consent  X c         
Inclusion/exclusion criteria  X         
Demographics  X         
Medical/surgical & smoking history  X         
Concomitant medication review  X d X X X X X X X X 
Full physical examination e X         
Urological examination f X X      X X 
Clinical assessment before study drug instillation  g   X X X X X   
Height and weight  X         
Vital signs h  X X X X X X X X X 
Hematology/serum chemistry i  X X      X X 
Urinalysis j  X X X X X X X X X 
Pregnancy test (WOCBP only) k  X       X X 
Adverse event review and evaluation l  X X X X X X X X X 
CT Urogram, retrograde pyelogram, or MRI m X         
Cold cup biopsy n X         
Cystoscopy (white light)  X       X  
Urine cytology  X o       X  
Administer study treatment p   X X X X X X   
Patient questionnaire q   X X X X X X X 
Home health professional questionnaire r   X X X X X   
Investigator questionnaire s        X X 
Telephone call for safety oversight after home instillation  t    X X X X X   
Biopsy remaining lesions if indicated  by [CONTACT_113511]         X u  
Disease Assessment         X u  
Study Exit         X v  
Complete eCRFs  X X X X X X X X X 
AE = adverse event; AESI = adverse event of special interest; CT = computed tomography; d = day; D = visit day; eCRF = electronic case report form; EOS = end-of- study; ET = early 
termination; HG = high-grade; ICF = informed consent form;  LG = low-grade; MRI = magnetic resonance imaging; NA = not applicable; NMIBC = non-muscle- invasive bladder cancer; 
SAE = serious adverse event; UC = urothelial carcinoma; UTUC = upper tract urothelial carcinoma; W = visit week; WOCBP  = women of child- bearing potential.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
13 a. The Screening Period is up to 14  days for patients who do not need a Screening biopsy and up to 28 days for patients who need a Screening biopsy. Screening procedures are required to 
provide evidence of LG NMIBC and no evidence of HG disease.  
b. Windows are provided to accommodate patient logistics in scheduling. Treatment instillations should occur 6 to10 days apart. Every effort should be made to minimize the time interval 
between diagnosis and Treatment Visit 1  (the maximum interval from end of Screening to first instillation should be ≤ 7 days). 
c. Obtain written informed consent before any study- related procedures are performed.  
d. Any past therapy (eg, pharmacological or surgical interventions) related to UC will be recorded during Screening.  
e. A full physical examination will be performed at the Screening Visit by a physician at the investigati ve site (Section 9.3.1 ). Additional full physical examinations may be performed 
during the study if clinically indicated.  
f. A urological examination will be performed at the Screening Visit, Treatment Visit 1 , and at the 3- month Visit (or ET) by a physician at the investigative site (Section 9.3.1 ). The  
urological examination should b e performed before cystoscopy at relevant visits. Additional urological examinations may be performed during the study if clinically indicated. Any 
clinically relevant changes in urological examinations will be recorded on the AE sections of the eCRF . 
g. Clinical assessment will be performed before study drug instillation. Body systems to be reviewed include general appearance and urethral meatus ( Section 9.3.1 ). Abnormal findings 
observed at home instillation visits will be documented and reported by [CONTACT_113517].  
h. Vital signs include body temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure ( Section 9.3.2 ).  
i. Hematology and serum chemistry samples will be tested at the local laboratory. Parameters to be analyzed in this study are listed in Section 9.3.3. Other parameters that are part of the 
local laboratory standard panel may be reported in addition to the protocol -specified parameters. 
j. Dipstick on- site and at home ; culture and sensitivity added at Screening, and when otherwise clinically indicated, if suggestive for infection (at local laboratory) ( Section 9.3.4 ). 
k. Urine or serum pregnancy test (at local laboratory) . See Section 9.3.5  for the definition  of a female of childbearing potential. 
l. Adverse events will be collected from the signing of the ICF until the 3-month Visit (EOS). The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 9.4.1 , Section 9.4.5 , and Section 9.4.6. Investigators are to report AEs (including AESIs) in a consistent 
manner as described in Section 9.4.[ADDRESS_126619] Urogram, retrograde pyelogram, or MRI (if other tests are contraindicated) to rule out UTUC (acceptable if performed within 6  months before Screening Visit) (results assessed locally).  
n. A single representative cold cup biopsy to confirm LG tumor will be performed only if not already performed within 8  weeks before Screening Visit. This is a diagnostic biopsy to 
demonstrate histopathology of tumor and resection of the tumor is not to performed. 
o. No cytology needed if results from a prior cytology within 6 weeks before Screening are available.  
p. Treatment Visit 1 will occur at the investigative site and study treatment instillation will be  performed by a qualified physician. Treatment Visits  2 to 6 will occur at the patient’s home 
and study treatment instillation will be performed by a properly trained and qualified home health professional. The patient will be monitored for AEs during and for at least 60 minutes 
after each study treatment instillation. If the patient withdraws consent for in- home instillation of study treatment, the patient may continue treatment and scheduled assessments at the 
investigative site ( Section 8.1.3 ). Administration of study treatment will be documented in the patient file, eCRF, and in the Drug Administration Records ( Section [IP_ADDRESS]).  
q. Patient questionnaire: Part [ADDRESS_126620] be completed after home instillation of study treatment  at Treatment Visits 2 to 6; Part [ADDRESS_126621] be completed at the 3- month Visit (EOS) or ET Visit) 
(Appendix A ). 
r. Home health professional questionnaire: Part [ADDRESS_126622] be completed after home instillation of study treatment at Treatment Visits  2 to 6; Part [ADDRESS_126623] be completed after home instillation 
of study treatment at Treatment Visits 3 to 6 (Appendix B ). 
s. Investigator questionnaire: M ust be completed at the 3- month Visit (EOS)  or ET Visit (Appendix C ). 
t. The home health professional will call the patient  1 day (+1  day) after each home instillation of study treatment to monitor for safety (Section [IP_ADDRESS] ). 
u. Efficacy assessment (approximately [ADDRESS_126624] instillation of study treatment) . Biopsies may be needed at the 3- month Visit (EOS) if any remaining lesions are visualized 
during cystoscopy ( Section 9.2). 
v. Following the 3- month Visit, all patients will exit the study and continue with standard of care  according to their treating physician. 
 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126625]  aspartate aminotransferase  
BCG  Bacillus Calmette -Guérin  
CBC  complete blood count  
CFR  Code of Federal Regulations  
CI confidence interval  
CNE  clinical nurse educator  
CR complete response  
CRR complete response  rate 
CTCAE  Common Terminology Criteria for Adverse Events  
DCR  durable complete response  
eCRF  electronic case report form  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
EOS  end-of-study  
ET early termination  
FDA  Food and Drug Administration  
GCP  Good  Clinical Practice  
GMP  Good Manufacturing Practice  
HG high-grade  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IP investigational products  
IR intermediate risk  
IRB Institutional Review Board  
LG low-grade  
LPLV  last patient last visit  
LUTS  lower urinary tract symptoms  
MedDRA  Medical Dictionary for Regulatory Activities  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126626] quality complaint  
PT preferred term  
QC quality control  
QTL  quality tolerance limit  
SAE  serious adverse event  
SAP statistical analysis plan  
SEER  Surveillance, Epi[INVESTIGATOR_623], and End Results  (Program)  
SMP  Study Monitoring Plan  
SoA Schedule of Activities  
SRT safety review team  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TEAE  treatment -emergent adverse event  
TURBT  transurethral resection of bladder tumor s 
UADR  unexpected adverse drug reaction  
UC urothelial carcinoma  
ULN  upper limit of normal  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
UTI urinary tract infection  
UTUC  upper tract urothelial carcinoma  
 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126627] common cancer in the US,  with an expected 81,000 new cases 
diagnosed in 2020 ( ACS, 2020). At the time of diagnosis, 75% of patients present with NMIBC 
(Babjuk et al, 2019; Monteiro et al, 2019). NMIBC includes a clinically heterogeneous group of 
cancers with a wide range of recurrence and progression probabilities ( Chang et al, 2016). 
Theref
ore, treatm ent guidelines recommend classifying patients with NMIBC as being at low, 
intermediate, or high  risk of disease recurrence and/or progression  (Babjuk et al, 2019 ; Chang 
et al, 2016 ; Kamat et al, 2014). While the management of low risk and high -ri sk patients appears 
clear, the best treatment option  for intermediate risk patients  remains undefined ( Monteiro et al, 
2019). Based on analysis of the Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) Program 
SEER*Stat Database, UroGen  estimates that LG IR NMIBC represents approximately 25% of 
newly diagnosed bladder cancer cases in t he US ( SEER Program, 2019). 
The current standard of care for treatment of LG IR NMIBC is TURBT under general anesthesia 
(NCCN, 2020 ; Chang e t al, 2016). Due to the persistent and recurrent nature of the disease (30% 
to 50% recur at 1 year; Babjuk et al, 2019), patients with LG IR NMIBC  ofte n endure repeated 
TURBTs under general anesthesia, which research has shown to be associated with significant postoperative and long- term morbidity  and an increased risk of overall death ( Erikson et al, 2020; 
Pereir 
a et al, 2019 ; Avallone et al, 2017; Ghali et al, 2016; Matulewicz et al, 2015; Patel et al, 
2015; De Nunzio et al, 2014; Hollenbeck et al, 2006; Balbay  et al , 2005 ). Rates of 30 -day 
complications (11%), unplanned hospi[INVESTIGATOR_5394] (5%), and mortality (1%) following 
TURBT  yield a significant number of patients at risk given the high volume of this procedure 
(Erikson et al, 2020; Patel et al, 2015; Rambachan  et al, 2014 ). The totality of evidence, 
including procedural limitations (eg, incomplete resection of tumors;  Daneshmand et al, 2018; 
Miyake
 et al, 2016),  postoperative complications, and t he high recurrence rate of NMIBC , 
suggests that the current, primarily surgical approach to treatment is suboptimal.  
Short- term, chemoablative therapy with UGN -102  has the potential to serve as a primary 
nonsurgical treatment option for LG IR NMIBC, especially among this population of 
predominantly elderly and multimorbid patients , by [CONTACT_113518]. Studies in the peer -reviewed literature (Lindgren et al, 2020;  Most afid et al, 2020; 
Colombo et al, 2012) and data from the UGN- [ADDRESS_126628] that 
chemoablation  with mitomycin may obviate the need for surgery in some patients or reduce the 
perioperative morbidity  associated with surgery secondary to lower volume disease, and may be 
associated with fewer clinically significant adverse effects.  
UGN-102 
UGN- 102 (mitomycin) for intravesical solution  is a reverse thermal gel formulation of 
mitomycin designed for initial nonsurgical treatment of LG IR NMIBC, and to potentially 
obviate the need for repetitive TURBT. The reverse thermal properties of UGN -102 allow for the 
local administration of mitomycin as a liquid  in a cooled state, with subsequent conversion to a 
semi -solid gel depot at body temperature following instillation into the bladder cavity. The gel 
slowly disintegrates and is excreted by  [CONTACT_113519] , allowing for the sustained release of 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
17 mitomycin over a period of 4  to 6 hours. The prolonged exposure of tumor cells to mitomycin 
leads to improved chemoablation compared with aqueous preparations of mitomycin. 
The efficacy and safety of UGN -102 for the treatment of patients with LG IR NMIBC was  
evaluated in a Phase 2b , single -arm, multicenter study (BL005). Intravesical instillation of 
UGN-102 once weekly for 6 weeks resulted in  high rates of CR at 3  months and durable 
complete response ( DCR) at 12 months after the start of study treatment.  A total of 63 patients 
were enrolled and treated with UGN -102. Forty -one (65.1%) patients achieved the primary 
endpoint of CR at [ADDRESS_126629] instillation of UGN -102 (95% CI of CR rate: 52.0, 
76.7), and 25/41 (61.0%) patients had a DCR at [ADDRESS_126630] instillation (95% CI  of 
DCR rate: 44.5, 75.8). The 9- month  duration of response rate  as estimated by [CONTACT_8761] -Meier 
method was 72.5% (95% CI: 54.4, 84.3), ie, the probability that a patient will maintain CR for at 
least 9 months is 7 2.5%. The overall safety profile of UGN -102 was favorable , with primarily 
mild to moderate adverse events (AEs), no treatment -related serious adverse events (SAEs)  or 
hospi[INVESTIGATOR_602], low number of treatment discontinuations, and no clinically meaningful trends 
or pattern of changes identified in laboratory parameters, vital signs, or physical examinations.  
Based on the favorable tolerability profile  and th e vulnerability of this patient population, the 
intent of this study is to demonstrate that UGN -102 may be safely and feasibly administered in the 
home setting.  Further details regarding the development of UGN-102 can be found in the UGN-102 
Investigator’s Brochure (IB). 
2.1. Study Rationale  
This study aims to demonstrate that  home instillation of UGN -102 is a feasible alternative to 
instillation in a clinical setting . Potential advantages of home instillation  include but are not 
limited to:  
• moving health care out of the clinical setting and into a patient’s home, potential ly 
reducing hospi[INVESTIGATOR_113493] . 
• decreased risk of exposure to infections  observed in the healthcare setting . 
• simplifying travel logistics , decrease travel expenditures, decrease clinic waiting periods 
for the patient.  
• decreased  burden to family members who might otherwise need to transport patient to 
and from clinical setting . 
• receiving cancer treatment in a familiar environment.  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126631] symptoms (LUTS) may develop. These symptoms are well 
known in relation to standard mitomycin instillations and are not specific to UGN-102. Urine 
tests, including urinalysis and urine culture as indicated, will be checked regularly during the study to monitor for potential UTI . Any signs and/or symptoms of UTI  will be treated by [CONTACT_113520].  
Toxicity Associated with Systemic Absorption/Local Irritation  
Bladder toxicity and rarely bone  marrow toxicity (thrombocytopenia and leukopenia) are 
considered possible risk s for patients  when mitomycin  is administered topi[INVESTIGATOR_897] . Complete blood 
count and renal and liver function tests will be checked during the study ( Table 4), and the 
Investigator will follow any  clinically significant abnormality until it is resolved , stabilized , or 
otherwise managed  (Section 9.3.3). 
Allergic Response to Mitomycin  
Allergic reactions during mitomycin bladder instillations are well described and have been 
observed during previous studies with UGN-102. Toxicities were generally manageable by 
[CONTACT_113521], and with systemic steroids as needed. Signs of an allergic response will be closely monitored during the study and managed 
by [CONTACT_113522]. 
Instill ation Procedure  
The insertion of a urethral catheter requires manipulation of the urethra and bladder . Some pain 
and discomfort are expected  given the intravesical route of administration .  
Potential risks of urethral catheterization include catheter associated  UTI s, soreness, bleeding, 
bruising, and kidney infections. 
The first study treatment  instillation will be performed at the investigative site  by a qualified 
physician. Treatment Visits  2 to 6 will occur at the patient’s home and study treatment 
instillation will be performed by a properly trained and qualified home health professional. To 
the extent possible, the same home health professional will perform home instillation of study 
treatments for a given patient.  
If the assigned home health professional is unable to perform the study treatment instillation on a 
scheduled dose day, another trained and qualified home health professional will perform the 
required study treatment instillation (Section [IP_ADDRESS]).  
The patient will be monitored for AEs  during and for at least 60 minutes after each study  
treatment instillation .  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
19 2.2.2. Benefit Assessment  
The potential advantages of instillation of mitomycin in hydrogel include: 
• Extended exposure of drug for up to 6 hours (compared with 1.[ADDRESS_126632] 
instillation). Published literature indicates that duration of tumor exposure to 
chemotherapy is critical to its ablative response. Thus, the effectiveness of tumor ablation is increased by [CONTACT_113523].  
• The hydrogel protects mitomycin  from being diluted by [CONTACT_113524], which leads to longer 
stable chemotherapy concentration levels.  
These characteristics of UGN -102 (mitomycin + sterile hydrogel) are expected to improve 
mitomycin treatment efficacy and provide an alternative mode of ablation for NMIBC, which may be simpler and potentially better tolerated than current treatment modalities.  
Instillation Procedure  
Potential benefits of providing medical care at home  include patient convenience, comfort and 
logistical ease, decreased risk of nosocomial infections, decreased exposure to others who may 
transmit infections such as the COVID-19 virus, influenza, or common “cold” virus 
(eg, rhinoviruses and adenoviruses), and decreased burden on family members who might 
otherwise be responsible for transporting patients to and from procedures . Other potential 
benefits include increased patient engagement  and compliance in study procedur es.  
2.2.3. Overall Benefit -Risk Conclusion 
Overall, based on the efficacy and safety  resul
 ts observed to date , UGN-102 has a favorable 
benefit- risk profile for the treatment of LG IR NMIBC. Additionally, based on the favorable 
tolerability profile  and the vulnerability of this patient population, home instillation of UGN-102 
may be a feasible treatment paradigm and offer potential advantages compared with instillation  
in a clinical  setting . 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
20 3. Objectives and Endpoints  
Objective  Endpoints  
Primary   
To evaluate the feasibility of home 
instillation of UGN -102 for treatment of 
patients with LG IR NMIBC  Feasibility will be assessed by [CONTACT_29657]:  
• Safety and tolerability  
o Reporting of AEs, including SAEs and AESIs  
o Standard clinical laboratory tests (hematology, 
serum chemistry, and urinalysis)  
o Physical examination and vital sign measurements  
• Rate of discontinuation from at home study treatment  
• Feedback from patients, home health professionals, and 
investigators via standardized questionnaires  
Secondary   
To evaluate the efficacy of UGN -[ADDRESS_126633] 
to complete response rate (CRR) at the 
3-month disease assessment  CRR  is defined as the proportion  of patients who achieved CR  
at the 3 -month Visit ([ADDRESS_126634] instillation of 
study treatment) as determined by [CONTACT_113511], for cause biopsy, and urine cytology  
AE = adverse event; AESI = adverse event of special interest; CR = complete response; CRR  = complete response 
rate; LG  IR NMIBC  = low-grade intermediate risk non -muscle -invasive bladder cancer; SAE  = serious  adverse event.  
 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
21 4. Study Design  
4.1. Overall Design 
This P hase 3b , open-label, single- arm, multicenter study is designed to assess the feasibility of 
home instillation of UGN -102 (mitomycin) for intravesical solution in approximately  10 patients  
with LG IR NMIBC. 
The primary objective of this study is to evaluate the feasibility of home instillation of UGN -102 as 
an alternative to instillation in a clinical setting. Feasibility will be assessed by [CONTACT_113525], rate of discontinuation from at home study treatment, and feedback from  patients , 
home health professionals, and investigators via standardized questionnaires. T he secondary 
objective of this study is to evaluate the efficacy of UGN -102 for the treatment of LG IR NMIBC 
following home instillation.  Efficacy will be assessed at the 3- month Visit ([ADDRESS_126635] 
instillation of UGN -102) by [CONTACT_113526], defined as the proportion of patients who achieved CR as 
determined by [CONTACT_113511], for cause biopsy, and urine cytology. 
Patients who provide informed consent will undergo a Screening Visit to determine eligibility . 
The Screening Period is up to 14 days for patients who do not need a Screening biopsy and up to 28 days for patients who need a Screening biopsy. Screening procedures are required to provide 
evidence of LG NMIBC and to rule out evidence of HG disease ( Section 1.3).  
A single representative cold cup biopsy to confirm LG tumor will be performed only if not already performed within 8 weeks before Screening. This is a diagnostic biopsy to demonstrate the histopathology of the tumor, and resection of tumor is not to be performed ( Section 1.3). 
Patients  will receive [ADDRESS_126636] 
instillation will be performed at the investigative  site and subsequent instillations will be 
performed at the patient’s home by a properly trained and qualified home health professional. 
The home health professional will call the patient  1 day (+1 day) after each home instillation of 
study treatment to monitor for safety  (Section 1.3 ).  
The UGN-102 concentration to be used in this study will be 1.33 mg mitomycin per 1 mL 
admixture. The volume of UGN -102 admixture to be instilled will be 56 mL (75  mg of 
mitomycin) (Section 7.1.3).  
At each home instillation visit, the patient and home health professional will complete a feasibility questionnaire . In addition, the patient and investigator will complete a feasibility 
questionnaire a t the 3 -month Visit ( EOS ) or ET Visit ( Section 1.3 and Section 9.9 ). 
Patients will return to the clinic for the 3 -monthVisit (7  weeks  ± 1 week after the final instillation 
of UGN-102) for determination of response to treatment.  
Response to study treatment  will be determined based on visual evaluation by [CONTACT_113511] (white 
light) (appearance, number, and size of any remaining lesions), interpretation of urine cytology, and for cause biopsy and histopathology of any remaining lesions ( Section 9.2.2). Any lesions or 
suspect tissue must be biopsied to evaluate for persistence of disease. 
If an unscheduled visit is required during the study, assessments should be performed as 
appropriate to the needs of the visit. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
22 Safety will be evaluated based on  vital signs, physical examination, laboratory assessments, and a 
review of AEs. All safety data will be reviewed on an ongoing basis by [CONTACT_1034], including close 
review and follow up of any unexpected AE assessed as related to UGN-102 ( Section  [IP_ADDRESS].3), 
and qualified per National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) as Grade 3 or 4 ( Section [IP_ADDRESS].1).  
A patient will be considered to have completed the study if the patient completes the 3-month Visit in accordance with the Schedule of Activities (SoA) ( Section 1.3 ). 
Following the 3- month Visit, all patients will exit the study and continue with standard of care 
according to their treating physician. 
End-of-study  is defined as the LPLV. The EOS will be declared after all patients have completed 
the 3- month Visit.  
4.2. Scientific Rationale for Study Design 
UroGen  estimates that LG IR NMIBC represents approximately 25% of newly diagnosed 
bladder cancer cases in the [LOCATION_002] ( SEER Program, 2019). While TURBT remains the 
current surgical standard of care  for treatment of  LG IR NMIBC ( NCCN, 2020 , Chang et al, 
2016), Study BL005 (OPTIMA II) showed a favorable efficacy and safety profile with 6 once 
weekly intravesical instillations of UGN -102 (75 mg mitomycin) as an alternative to surgery , and 
demonstrated durable clinical response in patients with LG IR NMIBC ( Huang et al, 2020).  
Intravesical instillation of UGN -102 may become a viable alternative to TURBT  for these 
patients and is under evaluation in a Phase 3 study (BL006). One of the benefits of UGN-102 is 
the ability to safely administer in the outpatient setting by [CONTACT_113527]. This study aims to demonstrate that home instillation of UGN -102 is a feasible alternative to instillation in a clinical setting , which might 
mitigate some of the challenges in the patient experience (logistical, expense, and comfort)  when 
receiving treatment for LG IR NMIBC.  
The COVID -19 pande
 mic has created an unprecedented need to re -evaluate the entirety of global 
healthcare and specifically the cancer care delivery system. Home instillation of antitumor therapy 
is not new outside the US, and internationally approximately 5%-10% of patients diagnosed with a 
range of cancer s receive antitumor therapy at home ( Lal et al, 2013; Luthi et al, 2012; Innominato 
et al, 2016 ). This global practice could be considered a model for feasibility in the US for in -home 
a
ntitumor therapy  delivery . Pointedly so during an unprecedented time when in -home consultation 
and care are increasingly  sought, becoming familiar to patients, and recognizably viable by [CONTACT_113528] ; all thereby , mitigating increased risk of morbidity and 
mortality from COVID -19 and other readily transmissible infectious diseases (Handley and 
Bekelman, 2019; Handley et al, 2020 ; Laughlin et al, 2020; Dai  et al, 2020).  
A re-evaluation of in-home delivery of cancer treatments in the US is not only a reasonable task  
during the current pandemic, but a potential viable option for post-pandemic practice leading to care that benefits the overall health, well -being and safety of patients diagnosed with certain 
cancers. Intravesical catheterization delivery of immunotherapy has been performed by [CONTACT_113529] 45  years ( Fuge et al , 2015 ). Thus, 
the procedure is foundational and having  the flexibility to receive treatment by a trained and 
qualified home health professional at home may change the landscape of LG NMIBC treatment. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
23 Further, f easibility for in -home treatment instillation of UGN-102 may be tested in this 
subpopulation of cancer patients given that LG IR NMIBC has a well -understood clinical 
behavior over time (Marcq et al, 2019; Hurle et al, 2018; Tiu et al, 2014 ) and the recent 
promising results of the OPTIMA II trial ( Huang et al,  2020 ).  
4.3. Justification for Dose   
The UGN-[ADDRESS_126637] completed the 3- month Visit  (7 weeks ± 1 week  after 
the final instillation of UGN -102). 
The EOS is defined as LPLV.  
5. Study Population  
Adult patients  with  LG IR NMIBC who are willing to undergo study treatment at home will be 
enrolled in the study.  
5.1. Inclusion Criteria  
Patients are eligible to be included in the study only if all the following criteria apply: 
1. Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the ICF  and in this protocol. 
2. Patient must be ≥  18 years of age, at the time of signing the ICF . 
3. Patient who has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by [CONTACT_113512] 8  weeks before Screening. 
4. Has IR disease, defined as having 1 or 2 of the following: 
• presence of multiple tumors . 
• solitary tumor >  3 cm. 
• recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis at 
the initial Screening Visit). 
5. Negative voiding cytology for HG disease within 6 weeks before Screening . 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
24 6. Has adequate organ and bone marrow function as determined by [CONTACT_113530]:  
• Leukocytes ≥  3,000/μL (≥  3×109/L). 
• Absolute neutrophil count ≥  1,500/μL (≥  1.5×109/L). 
• Platelets ≥  100,000/μL (≥  100×109/L). 
• Hemoglobin ≥  9.0 g/dL. 
• Total bilirubin ≤  1.5 × ULN. 
• AST/ALT ≤  2.5 × ULN. 
• ALP ≤  2.5 × ULN. 
• eGFR ≥  30 mL/min . 
7. Has no evidence of active urinary tract infection at the Screening  and baseline visits. 
8. Patient is willing to receive instillations of UGN -102 at home (ie, Treatment Visits  2 to 6) 
by [CONTACT_113514]. 
9. Contraceptive use by [CONTACT_113515]. Women of childbearing 
potential (defined as premenopausal women who have not been sterilized), including 
female patients and female partners of male patients, must be willing to use [ADDRESS_126638] a low failure rate (ie, less than 1% per year) when used consistently and correctly include implants, injections, 
combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only 
hormonal) , condoms with spermicide, sexual abstinence, or vasectomized partner.  
10. Has an anticipated life expectancy of at least the duration of the trial.  
5.2. Exclusion Criteria  
Patients are excluded from the study if any of the following criteria apply:  
1. Received BCG treatment for UC within previous 1 year. 
2. History of HG bladder cancer ( papi[INVESTIGATOR_113494]) in the past 2 years. 
3. Known allergy or sensitivity to mitomycin that in the Investigator’s opi[INVESTIGATOR_113495] . 
4. Clinically significant urethral stricture that would preclude passage of a urethral catheter  
5. History of: 
• neurogenic bladder . 
• active urinary retention . 
• any other condition that would prohibit normal voiding. 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126639] or current T1 UC, muscle invasive UC (ie, T2, T3, T4), metastatic UC , or concurrent 
UTUC. 
7. Has an underlying substance abuse or psychiatric disorder such that, in the opi[INVESTIGATOR_684], the patient would be unable to comply with the protocol. 
8. History of prior treatment with an intravesical chemotherapeutic agent in the past 2  years 
except for a single dose of chemotherapy immediately after any previous TURBT. 
9. Has participated in a study with an investigational agent or device within 30  days of 
enrollment.  
5.3. Lifestyle Considerations  
Not applicable. 
5.4. Screen Failures  
Screen failures are defined as patients who consent to participate in the study but are not enrolled or started  on study treatment. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure patients to meet the Consolidated Standards of Reporting 
Trials publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demography, screen failure details, eligibility criteria, and any SAEs . 
Re-screening of patients is allowed in this study. 
5.5. Strategies for Recruitment and Retention  
A sufficient number of patients will  be screened to ensure that approximately  10 patients with 
LG IR NMIBC are enrolled in the study. Patients who discontinue before the EOS V isit may be 
replaced at the Sponsor’s discretion. The study will be conducted at approximately 5 investigative sites in the US  that provide care to patients with bladder cancer.  
5.6. Criteria for Temporarily Delaying Administration of Study 
Treatment   
If at any time during the study the Investigator identifies myelosuppression, evidence of an 
active UTI , or any other significant clinical event or laboratory derangements outside the pre-
defined parameters, treatment may be  postponed for up to 4 weeks until the clinical event 
resolves and/or laboratory values improve (Section  [IP_ADDRESS]).   
CONFIDENTIAL  Protocol BL010 version 1.0 
 
26 6. Qualified Health Care Personnel  
The study will be conducted by [CONTACT_113531] , clinical nurse educators (CNEs),  
and qualified home health professionals. 
6.1. Clinical Nurse Educators  
This study will contract CNEs to train pharmacy personnel on study treatment preparation and 
study personnel (eg, investigators and home health professionals)  on the UGN-102 instillation 
procedure. The role of the CNE in the current study will include , but may not be limited to: 
• conduct training on UGN- 102 instillation procedures for the Principal Investigator, 
sub-investigator(s), home health professionals, and other relevant personnel before the 
first study treatment administration.  
• be present for training purposes during the first study treatment administration . 
• conduct training for pharmacy personnel on UGN-102 study treatment preparation as per the Instructions for Pharmacy .  
• following training, attend the first pharmacy preparation, if allowed by [CONTACT_1714]. 
• attend at least the first study treatment administration at the patient’s home . 
6.2. Home Health Professionals  
This study will contract licensed home health professionals to administer the study treatment at 
the patient’s home for Treatment Visits  2 to 6. The role of the  home health professional at each 
home visit will include , but may not be limited to: 
• communicate with site study team and coordinate patient’s home visits  for study 
treatment administration .  
• attend the patient’s first treatment at the investigational study site.  
• attend the patient’s home for subsequent instillations per training . 
• coordinate study drug and study suppl ies to be available at the patient’s home for home 
administration.  
• conduct a clinical  assessment , measure vital signs, and document the findings in the 
electronic Case Report Form  (eCRF ). 
• review concomitant medications. 
• review adverse events and monitor patient for AEs for at least [ADDRESS_126640] -instillation.  
• call the patient approximately 24 hours after instillation to see how the patient is feeling 
and if there are any reported  adverse events. 
• remove all study- related hazardous waste from the patient’s home at the end of the 
home visit. 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126641] s (IPs) or marketed product(s)  intended 
to be administered to a study patient according to the study protocol. 
7.1. Study Treatment Administered 
7.1.1. Study Treatment Description   
The UGN- 102 admixture for intravesical instillations contains mitomycin 75  mg in 56 mL 
admixture (1.33 mg mitomycin per 1 mL). The UGN-102 admixture is prepared in advance of 
use by [CONTACT_1714], and it is stable for up to 48 hours before administration at room temperature (this time is supported by [INVESTIGATOR_2993] -use stability data for up to 48 hours) plus 1  additional 
hour in ice to facilitate instillation . For  Treatment Visits  2 to 6, the assigned courier will obtain 
the prepared UGN-102 admixture from the site’s pharmacy and deliver it to qualified home 
health professional at the patient’s home for instillation .  
The UGN-102 single dose carton contains the below listed components ( Table 1 ). 
Table 1 UGN-102 Components  
Component  Quantity (per single 
dose carton)
 a Function 
Mitomycin for Solution (vial)  2 × 40 mg  Active Ingredient  
Sterile Hydrogel (vial)  1 × 60 mL Vehicle  
UGN-102 Admixture Labels 3 Admixture labels 
Instructions for Pharmacy  1 Instructions for admixture  
Instructions for Administration  1 Instructions for instillation  
WFI = water for injection.  
a For the proposed indication, each 40  mg vial of mitomycin will be mixed with 3  mL sterile WFI and 27  mL 
sterile hydrogel. A total of 56  mL of the 1.33  mg/mL admixture will be instilled in each patient. The hydrogel 
and mitomycin excess included are to allow for the required UGN -102 volume withdrawal from the vials . 
Refer to Figure 1  for the chemical structure of Mitomycin.  
Figure 1 Structure of Mitomycin, USP  
 
USP = [LOCATION_002] Pharmacopeia.  
 

CONFIDENTIAL  Protocol BL010 version 1.0 
 
28 Chemical name: 7 -amino -9α-metho3xymitosane  
Formula: C 15H18N4O5 
Molecular weight: 334.33 g/mol  
CASRN: 50 -07-7 
The vials of 40 mg mitomycin for solution are manufactured for UroGen Pharma Ltd., 9 
Ha’Ta’asiya Street, Ra’anana, Israel, by  
 [CONTACT_113532] a dry lyophilized powder in 
100 mL vials and will be stored at 20 °C to 25°C (68°F to 77°F) with excursions permitted 
between 15° C to 30°C (59°F and 86°F) and not to exceed 40 °C (104°F ). 
The contents of each mitomycin for solution vial are listed in Table 2 . 
Table 2 Vial Composition of Mitomycin for Solution  
Component  Quantity (mg per vial) Pharmaceutical Grade  Function 
Mitomycin  40 mg USP Active ingredient  
Mannitol 80 mg USP Bulking agent 
USP = [LOCATION_002] Pharmacopeia.  
The 60 mL of sterile hydrogel in a 100 -ml glass vial are manufactured for UroGen Pharma Ltd., 
9 Ha’Ta’asiya Street, Ra’anana, Israel, by  
 [CONTACT_113533] a 100- mL glass vial and will be stored at 
20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F and 86°F) 
and not to exceed 40°C ( 104°F ) (Refer to Label for Hydrogel Vial).  
The contents of each sterile hydrogel vial are a proprietary mixture of poloxamer 407, 
hydroxypropyl methyl cellulose, polyethylene glycol, and water for injection. 
The components of UGN-102 are produced under aseptic conditions and according to current 
Good Manufacturing Practice (GMP) (European Commission, May 2003 Guidelines). The 
UGN-102 lots to be used in this study are tested and released under supervision and approval by 
[CONTACT_13679]’s Designee. 
7.1.2. Preparation  and Administration Ancillary Supplies  
Ancillary supplies used to prepare and administer the study treatment are detailed in the 
Instructions for Pharmacy  and Instructions for Administration . Home health professionals will 
also be provided with a carrying bag containing commercially available ancillary items necessary 
for home instillation of study treatment as detailed in the Study Distribution Manual. 
7.1.3. Administration  and Dosing  
[IP_ADDRESS]. Administration  
Patients will receive  [ADDRESS_126642] be available for verification by [CONTACT_1034]’s site monitor during on- site 
monitoring visits. Unused or expi[INVESTIGATOR_113496]-[ADDRESS_126643] be documented on 
the drug return form. 
The Investigator agrees to neither dispense the study treatment from, nor store it at, any site other 
than the site agreed upon with the Sponsor. 
Unusable UGN-102 single dose cartons will be marked “not for use” in pen over the label and 
stored separately from usable UGN -[ADDRESS_126644] for additional supplies has been issued to 
the Sponsor’s Designee. 
Following completion of drug accountability by [CONTACT_941] c linical research associate, used study 
treatment vials should be discarded locally according to local institution guidelines for cytotoxic 
waste destruction. Discarding/destruction of the used UGN- [ADDRESS_126645] be 
documented in the drug disposal form.  
7.2.2. Formulation, Appearance, Packaging, and Labeling  
The formulation of the study treatment and the contents of UGN -102 is described in 
Section  7.1.1. All clinical supplies will be packaged and labeled in compliance with GMP 
guidelines. All information regarding study treatment provided will be appropriately documented 
(ie, batch records, Certificate of Analysis, etc.). The original product packaging will be used in 
the study (UroGen Pharma Ltd., Israel). 
7.2.3. Product Storage and Stability  
UGN-[ADDRESS_126646] be stored at a controlled temperature of 20°C to 25°C (68°F to 
77°F), excursion permitted between 15°C and 30°C (59°F and 86°F). Exposure to excessive heat 
(over 40°C, 104°F) should be avoided. 
The clinical supplies storage area at the investigative site must be monitored by [CONTACT_113534]. 
Documentation of temperature monitoring should be maintained and available for review. 
7.2.4. Admixture  
The UGN- 102 admixture (sterile hydrogel mixed with mitomycin) is stable for 48 hours at 20°C 
to 25°C (68°F to 77°F), excursion permitted between 15°C and 30°C (59°F and 86°F). Exposure 
to excessive heat (over 40°C, 104°F) should be avoided. Up to 1 hour before administration, the admixture should be cooled down to between -3°C (27°F) and +5°C (41°F) in order to liquify the 
UGN-102. The elapsed cooling time must be documented, which includes the length of time at 
room temperature, as well as length of time in ice . 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126647] related to manufacturing, labeling, or 
packaging; ie, any dissatisfaction relative to the identity, quality, durability, or reliability of a 
product, including its labeling or packaging integrity. In such cases, and also in cases of 
temperature deviation, either during transport, storage,  or preparation at the pharmacy , or during 
transport to patient’s home, the Investigator is  responsible for notifying the Sponsor about the 
defect/temperature deviation. Any PQCs must be reported to the Sponsor/Sponsor Designee using:  or . 
Reporting must be done upon first awareness, and the site should await the Sponsor’s decision 
regarding the drug’s validity before drug dispensing. 
If the PQC is associated with an SAE, the investigational staff must report the PQC to the 
Sponsor/Sponsor Designee as described above and the SAE(s) must be reported according to 
Section 9.4.6 (Serious Adverse Event Reporting). The affected study products must be 
quarantined and marked “not for use” during investigation until a decision has been made regarding the drug’s usability. 
Product quality complaints may have an impact on the safety and efficacy of the product. Timely, 
accurate, and complete reporting and analysis of PQC information from clinical studies are crucial for the protection of patients, Investigators, and the Sponsor, and are mandated by 
[CONTACT_67819]. The Sponsor has established procedures in conformity with 
regulatory requirements worldwide to ensure appropriate reporting of PQC information; all clinical studies conducted by [CONTACT_113535]. 
7.3. Study Intervention Compliance 
The study treatment will be administered at the investigative site or in the patient’s home by 
[CONTACT_113536] . Each drug administration (including date, 
time, volume administered) will be documented in the patient’s file and eCRF ( Section [IP_ADDRESS]). 
7.4. Dose Modification  
Not applicable. 
7.5. Continued Access to Study Intervention after the End of the Study  
No study treatments will be administered to patients after the patient exits from the study.  
7.6. Treatment of Overdose  
Not applicable. 

CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126648]/Concomitant and Prohibited Therapy  
Any concomitant medication (including prescription or over-the-counter medications) that the 
patient is receiving at the time of enrollment or receives during the study and any past therapy 
(eg, pharmacological or surgical interventions) related to urothelial carcinoma  must be recorded 
in the eCRF along with: 
• Reason for use 
• Dates of administration including start and end dates  
• Route of administration  
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician. 
Prohibited concomitant medications include:  
• Systemic chemotherapy  
• Intravesical chemotherapy  
• Immunotherapy for bladder cancer treatment including but not limited to BCG 
• Pre-operative non- study chemotherapy  
In cases of symptomatic UTI, the patient will be treated with a course of antibiotics, and study 
treatment will be postponed until resolution. In the case of asymptomatic bacteriuria, the use of 
prophylactic antibiotics and postponement of study treatment is left to the discretion of the PI [INVESTIGATOR_113497]. 
The Sponsor Medical Monitor should be contact[CONTACT_113537]. 
7.7.1. Rescue Medicine  
No rescue therapy is planned for this study.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
33 8. Discontinuation of Study Treatment and Patient 
Discontinuation/Withdrawal  
8.1. Discontinuation of Study Treatment 
Discontinuation from study treatment does not mean discontinuation from the study, and 
remaining study procedures should be completed as indicated by [CONTACT_4690] (ie , 3-month 
Visit). If a clinically significant finding is identified (including, but not limited to, changes from baseline) after enrollment, the Investigator or qualified designee will determine if any change in patient management is needed. Any new clinically relevant finding will be reported as an AE.  
8.1.1. Temporary Withholding of Study Treatment   
If at any time during the study the Investigator identifies clinically significant  myelosuppression, 
evidence of an  active UTI, or any other significant clinical event or laboratory derangements 
defined by [CONTACT_113538], treatment may be
 postponed for up to 4 weeks until the clinical 
event resolves and/or laboratory values improve ( Section  [IP_ADDRESS]):  
• Absolute neutrophil count ≤  1,000/μL (≥  1.0×109/L). 
• Platelets ≤  80,000/μL (≤  80×109/L). 
• AST/ALT ≥  5 × ULN. 
• Laboratory  evidence of active UTI . 
8.1.2. Rechallenge 
No change in dose will be performed for patients who re -initiate their study treatment after 
temporary withholding ( Section 8.1.1).  
8.1.3. Withdrawal of Consent for Home Instillation of Study Treatment  
If the patient withdraws consent for in -home instillation of study treatment, the patient may 
continue treatment and all scheduled assessments at the investigative site .  
8.2. Patient Discontinuation/Withdrawal from the Study  
A patient in this study may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, or compliance 
reasons. 
A patient will be considered to have withdrawn from the study for any of the following: 
• Withdrawal of consent  
• Lost to follow -up 
• No longer being followed at the Investigator’s discretion 
• Protocol non- compliance  
• Pregnancy  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
34 • Patient experienced an AE that led to  study discontinuation 
• Death  
• Study is closed or terminated by [CONTACT_113539].  
At the time of early discontinuation from the study, if possible, an ET V isit should be conducted 
as shown in the SoA. See Section  1.[ADDRESS_126649] be taken if a patient fails to return to the clinic for a required study visit:  
• The site will attempt to contact [CONTACT_113540]/or should continue in the study. 
• Before a patient is deemed lost to follow -up, the Investigator or designee will make every 
effort to regain contact [CONTACT_10970] (where possible, 3 telephone calls and, if necessary, a certified letter to the patient’s last known mailing address or local equivalent methods). These contact [CONTACT_23526]’s study file.  
Should the patient continue to be unreachable, he or she will be considered to have withdrawn from the study with a primary reason of lost to follow -up. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
35 9. Study Assessments and Procedures 
Adherence to the study design requirements, including those specified in the SoA ( Section 1.3 ), 
is essential and required for study conduct. 
All Screening  evaluations must be completed and reviewed to confirm that potential patients 
meet all eligibility criteria. The Investigator will maintain a Screening  log to record details of all 
patients screened and to confirm eligibility or record reasons for Screening  failure, as applicable.  
Procedures conducted as part of the patient’s routine clinical management (eg, blood count) and 
obtained before signing of the ICF may be utilized for Screening  or baseline purposes provided 
the procedures met the protocol- specified criteria and were performed within the time frame 
defined in the SoA ( Section 1.3). 
9.1. Study Assessments and Procedures by [CONTACT_113541] 1.3  for the timing and schedule of all study procedures and assessments.  
If an unscheduled visit is required during the study, assessments should be performed as 
appropriate to the needs of the visit. 
9.2. Efficacy Assessments  
Efficacy will be assessed at the 3- month Visit.  
9.2.1. Measurements for Evaluation of Response at 3- month Visit 
Assessment of response will be based on the following: 
• Visual observation (white light cystoscopy) 
• Biopsy of remaining lesions, if applicable (non-complete response [NCR]  or 
suspected  tissue)  
• Voiding urine cytology 
9.2.2. Evaluation of Treatment Response at 3- month Visit  (Disease Assessment)  
Patient response will be evaluated according to the following criteria : 
• CR: A patient will be considered to have had CR if there is no detectable disease ( NDD ) 
at bladder . To determine NDD, the following conditions should be fulfilled: 
1. If visual assessment indicates no remaining tumors and urine cytology is not consistent with  the presence of UC, the patient has NDD and CR.  
2. If any remaining lesions appear, even if they appear necrotic, the physician should biopsy the lesion(s). If histopathology is negative, the patient should be classified as having CR; if positive for cancer, the patient should be classified as NCR.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
36 • NCR: A patient will be considered to have had NCR if there is evidence of disease 
under study: 
1. If tumors are still visible, all remaining lesions should be biopsied for histopathology 
and viability assessment. If histopathology still indicates cancer, then the patient is considered NCR. Note that biopsy results showing papi[INVESTIGATOR_113498]. 
• If evidence of disease is identified,  patients will be staged according to the 
Tumor- Node -Metastases classification and graded according to the 2004 World Health 
Organization classification of tumors. Any noted progression of tumor in terms of transition to high grade, muscle invasion, distant disease (local assessment) will be 
documented by [CONTACT_17072]. 
• In the rare event that the bladder is free of tumor endoscopi[INVESTIGATOR_897], but the cytology is 
consistent with UC, the urine cytology should be repeated. Note that atypi[INVESTIGATOR_113499], and that abnormal urine 
cytology findings require clinical context to support interpretation, particularly in the presence of a normal cystoscopy.  
1. If the repeat urine cytology is consistent with UC, the Investigator is required to 
exclude UC of the upper tract and occult carcinoma of the bladder or urethra.  
2. If UTUC is confirmed, the patient will be considered as CR for LG NMIBC. If 
UTUC is not confirmed, the Investigator must perform random bladder biopsies to 
examine the following 6 bladder mucosal sites: bladder floor, right wall, left wall, dome, posterior wall, and prostatic urethra (in males) or bladder neck (in females).  
3. If histopathology is negative, the patient should be classified as having CR; if positive for cancer, the patient should be classified as NCR . 
9.2.3. Pathological Evaluation 
Biopsies and urine cytology specimens obtained at Screening or any other visit should be 
evaluated by [CONTACT_12357] (pathologist)  facility . Pathology reports from local  laboratory 
facilities will be provided to Investigators. 
9.3. Safety Assessments  
The safety of study treatment will be assessed by [CONTACT_716]:  
• Evaluation (frequency, seriousness, severity, and type) of AEs including adverse events 
of special interest (AESIs)  
• Changes from baseline in laboratory values and incidence of measurements defined as potentially clinically significant  
• Clinically meaningful changes in physical examination findings including vital signs.  
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
37 9.3.1. Physical Examinations  
A full physical examination will be performed at the Screening Visit by a physician at the 
investigative site. A urological examination will be performed at the Screening Visit, Treatment 
Visit 1, and at the 3- month Visit (or ET) by a physician at the investigative site.  The 
examinations to be performed are summarized in Table 3 . Additional full physical examinations 
or urological examinations may be performed during the study if clinically indicated.  
A clinical assessment will be performed before study drug instillation. Abnormal findings 
observed at home instillation visits will be documented and reported by [CONTACT_113542].  
The patient’s height and body weight will be measured  during S creening . 
Table 3 Physical Examinations  
General/Full Physical 
Examination Urology -Oriented Physical 
Examination a Clinical Asse ssment  before 
study drug instillation  
General appearance  
Cardiovascular system  
Respi[INVESTIGATOR_113500] (head, eyes, ears, 
nose, and throat) and neck  
Abdomen 
Extremities  
Neurologic system  
Skin Urethral meatus  
Perineal skin and mucus 
membranes  
Scrotum and testes (for male patients)  
Lymphadenopathy  
Rectal examination (Screening visit only)  
Bimanual examination (female patients – Screening visit only)  General appearance  
Urethral meatus 
ET = early termination . 
a. Performed before cystoscopy at relevant visits . 
9.3.2. Vital Signs  
At each visit, the following vital signs measurements are to be taken : body t emperature , 
pulse rate, respi[INVESTIGATOR_697], and blood pressure.  
Blood pressure and pulse rate measurements will be assessed in a seated position with a 
completely automated device. Manual techniques will be used only if an automated device is not 
available.  
9.3.3. Clinical Safety Laboratory Assessments  
Samples for hematology and serum chemistry assessments will be collected according to the 
SoA in Section 1.[ADDRESS_126650] panel may be reported in 
addition to the protocol- specified parameters.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
38 Table 4 Laboratory Safety Assessments  
Liver Function Tests:  
AST  
ALT 
GGT  
ALP 
Total bilirubin  
Direct bilirubin  
Albumin  
Total protein  Kidney Function Tests:  
Creatinine  
Blood urea nitrogen  
Uric acid  
Sodium  
Potassium  
Bicarbonate  
Chloride  
eGFR (calculated in EDC)  Hematology Tests:  
CBC, including red blood cell indices 
and white blood cell differential 
Platelet count  
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; 
EDC = electronic data capture; eGFR = estimated glomerular filtration rate; GGT  = gamma -glutamyltransferase. 
Note: Laboratory samples will be kept per storage requirements as stated in the laboratory manual until shipped to the local laboratory for analysis.  
The Investigator must review the laboratory report, document this review, and record any 
laboratory abnormalities as clinically significant or not clinically significant. Any clinically 
significant changes should have a corresponding AE reported. The laboratory reports must be 
filed with the source documents.  
Abnormal laboratory findings associated with the underlying disease are not considered 
clinically significant unless judged by [CONTACT_27477]’s condition.  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study (eg, in case of either temporary discontinuation) or within [ADDRESS_126651] 
administered dose of study treatment (ie, in case of permanent discontinuation) should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant by [CONTACT_113543].  
If any clinically significant or other values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_737], the etiology should be identified, and the Sponsor 
notified. 
All protocol -required laboratory tests, as defined in Table 4, must be conducted in accordance 
with the laboratory manual and the SoA (Section 1.3).  
A local laboratory will be used in this study. If laboratory values from non-protocol specified 
laboratory tests performed at the institution’s local laboratory require a change in patient management or are considered clinically significant by [CONTACT_737] (eg, AE), then the results 
must be recorded.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
39 [IP_ADDRESS]. Other Significant Laboratory Derangements  
If at any time during the study the Investigator identifies clinically significant  myelosuppression, 
evidence of an active UTI , or any other significant clinical event or laboratory derangements 
defined by [CONTACT_113538], treatment may be  postponed for up to 4 weeks until the clinical 
event resolves and/or laboratory values improve:  
• Absolute neutrophil count ≤  1,000/μL (≥  1.0×109/L) 
• Platelets ≤  80,000/μL (≤  80×109/L) 
• AST/ALT ≥  5 × ULN  
• Laboratory  evidence of active UTI.  
9.3.4. Urinalysis  
At the visits specified in Section 1.3, samples will be collected for urinalysis, including culture and 
sensitivity (if indicative of infection) at the Screening Visit, and when otherwise clinically indicated.  
9.3.5. Pregnancy Testing  
A urine or serum pregnancy test will be conducted in female patients of childbearing potential at 
the visits specified in Section 1.3. A female is considered of childbearing potential unless:  
• At least [ADDRESS_126652] menstrual bleeding; or 
• She is without a uterus and/or both ovaries; or 
• She has been surgically sterile for at least 6  months before study treatment administration.  
9.4. AEs, SAEs , and Other Safety Reporting  
The definitions of AEs and SAEs can be found in Section  9.4.1. 
AEs will be reported by [CONTACT_102] (or, when appropriate, by a caregiver, surrogate, or the 
patient’s legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events as per instructions in Section 9.4.2 and remain responsible for following up all 
applicable AEs including those that are serious, considered related to the study treatment or 
study procedures, or that caused the patient to discontinue the study treatment or from 
participation in the study (Section 8).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section  9.4.1, 
Section  9.4.5, and Section 9.4.6. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
40 9.4.1. AEs and SAEs  
[IP_ADDRESS]. Definition of AE 
An AE means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention-related (21 CFR 312.32 [a]; European Directive 
2001/20/EC). An AE can therefore be any unfavorable and unintended sign, symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (“Note for Guidance on Good Clinical 
Practice” CPMP/ICH/135/95).  
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology, serum chemistry, or urinalysis) or other safety assessments (eg, electrocardiogram , radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the Investigator (ie, not related to 
progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment administration even though it 
may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected intervention -intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
• “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE.  
Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments, which are associated with the underlying disease, unless judged by [CONTACT_113544]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the patient’s 
condition. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
41 • Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day- to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
Any patient who reports an AE shall be examined by a doctor as soon as possible, making 
whatever intervention is necessary for the safety and well -being of the patient. All anomalies 
shall be monitored through to the patient’s recovery or clinical stabilization. Collected reportable 
AEs must be recorded in the eCRF using CTCAE version  5.0 ( CTCAE, 2017) to avoid the use of 
vague, ambiguous, or colloquial expressions. The Investigator shall evaluate all collected reportable AEs in terms of severity and their relationship with the product being tested, indicating the test results and the measures to be taken.  
[IP_ADDRESS]. Definition of SAE  
An AE or suspected adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes, at any dose:  
a. Results in death  
b. Is life- threatening  
• The term ‘life -threatening’ in the definition of ‘serious’ refers to an event in which the 
patient was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_113501] (usually involving 
at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be 
considered serious. 
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
42 e. Is a congenital anomaly/birth defect 
f. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_113545]. These events should 
usually be considered serious. 
o Examples of such events include invasive or malignant cancers, intensive treatment 
for allergic bronchospasm, blood dyscrasias, convulsions or development of 
intervention dependency or intervention abuse.  
[IP_ADDRESS]. Classification of an AE  
[IP_ADDRESS].1. SEVERITY OF EVENT  
The severity (intensity) of an AE is to be graded by [CONTACT_113546] 5.0 ( CTCAE, 2017). 
General rules are as follows:  
1 Mild: asymptomatic or mild symptoms; clinical or diagnostic observations only ; 
intervention not indicated. 
2 Moderate:  minimal, local, or noninvasive intervention (eg, packing, cautery) 
indicated; limiting age -appropriate instrumental activities of daily living (ADL). 
3 Severe or med
 ically significant but not immediately life -threatening ; hospi[INVESTIGATOR_12342]; disabling; limiting self- care ADL . 
4 Life-threatening consequences:  u rgent intervention indicated (SAE). 
5 Death related to AE  (SAE) . 
[IP_ADDRESS].2. RELATIONSHIP TO STUDY TREATMENT  (ASSESSMENT OF CA[LOCATION_003]LITY ) 
All AE/SAEs must have their relationship to study treatment/interventions and study procedures assessed by [CONTACT_113547]/her clinical judgment. In a clinical study, the study product must always be suspect. 
Investigators will be asked to grade each AE/SAE as either related (a reasonable possibility of a relationship) or unrelated.  
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to study treatment administration will be 
considered and investigated. 
The Investigator is instructed to also consult the IB in his/her assessment.  
For each collected reportable AE/SAE, the Investigator is instructed to  document in the medical 
notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
43 There may be situations in which an SAE has occurred, and the Investigator has minimal 
information to include in the initial report to the Sponsor’s Designee (via electronic data 
capture (EDC)/eCRF transmission). However, it is very important that the Investigator always 
make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor’s Designee (via EDC/eCRF transmission).  
The Investigator may change his/her opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updated causality assessment. 
[IP_ADDRESS].3. E
XPECTEDNESS  
The Sponsor will be responsible for determining whether an AE is expected or unexpected. An 
AE will be considered unexpected if the nature, severity, or frequency of the event is not 
consistent with the risk information previously described for the study treatment. 
An Unexpected Adverse Drug Reaction (UADR) is any noxious and unintended response that is 
related to the administration of an IP that has not been reported as expected in the IB (reference 
safety information for this study), either from previous clinical studies or the nonclinical studies.  
A Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R) is any UADR that at any dose also 
meets the criteria for SAE.  
9.4.2. Time Period and Frequency for Collecting AE and SAE Information 
The occurrence of an AE or SAE may come to the attention of study personnel during study 
visits and interviews of a study patient presenting for medical care, or upon review by a study 
monitor.  
Adverse events will be collected from the signing of the ICF until completion of the 3-month 
Visit ( Section 1.3).  Information will be captured on the appropriate eCRF including event 
description, date of onset, clinician’s assessment of severity, relationship to study treatment and 
study procedure (assessed only by [CONTACT_8703] a diagnosis), and 
date of resolution/stabilization of the event. All collected reportable AEs occurring while on 
study must be documented appropriately. All collected AEs will be followed to adequate resolution/stabilization.  
If the study patient’s condition deteriorates at any time during the study, it will be recorded as an 
AE. AEs reported from the time of study treatment administration will be considered as treatment- emergent adverse events (TEAEs).  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
At study visits per the SoA ( Section 1.3 ), the Investigator and/or designee should inquire about 
the occurrence of AE/SAEs since the last visit. The Investigator or designated investigational 
staff member should record the start date of all collected reportable events. Events will be 
followed for outcome information until resolution or stabilization and the dates of outcome must 
be recorded.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
44 All SAEs are to be recorded and reported to the Sponsor immediately and under no 
circumstance should this exceed 24 hours. The Investigator should submit any updated SAE 
data to the Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek information on AEs or SAEs after conclusion of 
the study participation . However, if the Investigator learns of any SAE, including a death, at any 
time after a patient has been discharged from the study, and he/she considers the event to be reasonably related to the study treatment or study participation, the Investigator must promptly notify the Sponsor within 24 hours. 
9.4.3. Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the patient is the preferred method to inquire about AE occurrences.  
9.4.4. Follow- up of AEs and SAEs  
After the initial collected AE/SAE report, the Investigator and/or de signee  is required to 
proactively follow each patient at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the patient is lost to follow -up (as 
defined in Section 8.3). Further information on follow -up procedures is provided in Section  9.4.6. 
9.4.5. Regulatory Reporting Requirements for SAEs 
Each patient must be given a patient card containing details of the contact [CONTACT_113548]/she should contact [CONTACT_113549]. 
Where required, patients will be examined at the center and will be clinically monitored until 
they recover. 
Expedited reporting to the Sponsor is required in the following conditions: 
1. Any SAE and follow- up SAE report, if required  
2. Death of study patient 
3. Pregnancy and outcome of the pregnancy 
The Investigator must inform the Sponsor/Sponsor Designee about the above by [CONTACT_113550]/Death or Pregnancy eCRF  within [ADDRESS_126653] came to 
his/her knowledge. 
Prompt notification by [CONTACT_113551] a study 
treatment under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study treatment under clinical investigation. The Sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and Investigators. 
An Investigator who receives an Investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
45 along with the Investigator File and will notify the IRB/IEC, if appropriate according to local 
requirements.  
Investigator safety reports must be prepared by [CONTACT_113552]. 
9.4.6. Serious Adverse Event Reporting  
The Investigator will immediately report to the Sponsor any SAE, whether or not considered 
study treatment-or study procedure related, including those listed in the protocol or IB and must 
include an assessment of whether there is a reasonable possibility that the study treatment or study procedure caused the event.  
All SAEs will be followed until satisfactory resolution or until the Investigator deems the event 
to be chronic or the patient is stable. Other supporting documentation of the event may be requested by [CONTACT_13679]’s Designee and should be provided as soon as possible. 
The Sponsor will be responsible for notifying the Food and Drug Administration ( FDA) of any 
unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in no case 
later than 7  calendar days after the Sponsor’s initial receipt of the information. In addition, the 
Sponsor must notify FDA and all participating Investigators in an Investigational New Drug 
safety report of potential serious risks, from clinical studies or any other source, as soon as possible, but in no case later than 15 calendar days after the Sponsor determines that the 
information qualifies for reporting.  
[IP_ADDRESS]. SAE Reporting Instructions  
The Investigator must inform the Sponsor within 24 hours  of becomi
 ng aware of an SAE (or 
updated SAE information) by [CONTACT_113553]/Death or Pregnancy eCRF . 
It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_113502]’s medical records to the Sponsor or designee in lieu of completion of the SAE/Death eCRF. 
There may be instances when copi[INVESTIGATOR_113503]. In this case, all patient identifiers, with the exception of the patient 
number, will be redacted on the copi[INVESTIGATOR_113504]. 
If a site receives a report of a new SAE from a study patient or receives updated data on a 
previously reported SAE when the electronic data capture tool has been taken off -line or is 
unavailable, then the site can report this information on a paper SAE form to the Sponsor (or 
designee) or Medical Monitor by [CONTACT_113554] [ADDRESS_126654] information for SAE reporting . 
Email: . 
Telephone (UroGen AE Call Center): .  

CONFIDENTIAL  Protocol BL010 version 1.0 
 
46 9.4.7. Pregnancy  
For any female patient who becomes pregnant while participating in the study, the Investigator 
shall immediately discontinue study treatment and ensure expedited reporting of the event within 
24 hours ( Section 9.4.5 ). The pregnancy will be followed to term and the outcome reported. 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported as such.  
The patient/pregnant female partner will be followed to determine the outcome of the pregnancy. 
The Investigator will collect follow -up information on the patient/pregnant female partner and 
the neonate, and the information will be forwarded to the Sponsor. 
Any post-study pregnancy-related SAE considered reasonably related to the study treatment by 
[CONTACT_9341] 9.4.5. While the 
Investigator is not obligated to actively seek this information in former study patients/pregnant female partner, he or she may learn of an SAE through spontaneous reporting. 
9.4.8. Disease- Related Events and/or Disease- Related Outcomes Not Qualifying as 
AEs or SAEs  
Not applicable. 
9.4.9. AESIs  
In this study, AESIs will be monitored on an ongoing basis through a regular review of adverse 
event listings . There are no requirements for the Investigator to make determination of AESIs 
and Investigators are to report all AEs in a consistent manner as described in Section 9.4.2.  
The list of AESIs is based on the most current safety profile of UGN -102 within the overall 
clinical development program and through ongoing review of emerging safety data. 
Current known AESIs include: 
• Allergic reaction to mitomycin (CTCAE Grade 3 or 4)  
• Voiding interruption due to urethral/penile edema (unrelated to prostatic hypertrophy) 
• Indication of b one marrow suppression 
• LUTS (CTCAE Grade 3 or 4) 
9.5. Pharmacokinetics  
Pharmacokinetic and pharmacodynamic parameters are not evaluated in this study. 
9.6. Genetics  and/or Pharmacogenomics 
Genetics are not evaluated in this study.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
47 9.7. Biomarkers  
Biomarkers are not evaluated in this study. 
9.8. Immunogenicity Assessments 
Immunogenicity is not evaluated in this study. 
9.9. Home Instillation Feasibility Questionnaires 
Home instillation feasibility questionnaires will be completed  by [CONTACT_102], the home health 
professional, and the I nvestigator  at the following time points. 
• Patient questionnaire  
o Part [ADDRESS_126655] be completed at the 3-month V isit (EOS ) or ET Visit  
• Home health professional questionnaire 
o Part [ADDRESS_126656] be completed after home instillation of study treatment at Treatment 
Visits  3 to 6  
• Investigator questionnaire  
o Must be completed at  the 3 -month V isit (EOS ) or ET Visit  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
48 10. Statistical Considerations  
10.1. Statistical Hypotheses  
The primary objective of this study is to evaluate the feasibility of home instillation of UGN -102 
for treatment of patients with LG IR NMIBC. Analyses are descriptive and exploratory in nature 
and no formal hypothesis will be tested.  
10.2. Sample Size Determination  
The sample size of this study ( approximately  10 patients) is based on feasibility.  
10.3. Analysis Set  
The Safety Analysis S et that includes all patients  who received any dose of UGN-102 will serve 
as the primary population for the analyses of safety and efficacy data in this study.  
10.4. Statistical Analyses  
10.4.1. General Considerations 
All measured variables and derived parameters will be listed individually and, if appropriate, tabulated using descriptive statistics. For categorical variables, summary tables will be provided giving sample size, absolute and relative frequency, and 95% CI for proportions using the exact 
approach. For continuous variables, summary tables will be provided giving sample size, 
arithmetic mean, standard deviation, coefficient of variation (if appropriate), median, minimum and maximum, percentiles, and 95% CI for means of variables as appropriate.  
10.4.2. Primary Endpoint(s)  
The primary endpoint is to assess the feasibility of home instillation of UGN -102 by 
• Rate of home instillation discontinuations 
• Feedback questionnaires from patients, home health professional, and investigator(s)  
• Safety profile of UGN -[ADDRESS_126657] clinical and laboratory tests 
(hematology and chemistry, urinalysis, physical examination, vital sign measurements, 
diagnostic tests, etc.) and through the collection of reports of adverse events (AEs) and 
serious adverse events (SAEs) including AEs of special interest.  
Home Instillation Discontinuations  
Descriptive statistics will be used to summarize proportion of patients discontinuing the home instillations. The frequency and  the percentages will be presented.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
49 Feedback Questionnaire  
Patient questionnaire 
Patients will be asked to rate their home instillation experience such as comfort, safety /concerns, 
communication , preference compared to  office instillation and overall experience at each home 
instillation visit after the instillation is completed. A trend in their responses will be measured 
descriptively. Patients’ home instillation recommendations will also be collected and 
summarized descriptively  at the 3-month Visit /EOS or ET Visit  (Appendix A ). 
Home health professional questionnaire  
Home health professionals will also be asked to complete a set of questionnaires after each home instillation visit. Data will be summarized descriptively  (Appendix B ). 
Investigator questionnaire  
Investigators will be asked to provide their feedback for each patient based on the experiences of the patient and the home health professional (s) at  the 3-month Visit/EOS or ET Visit  
(Appendix C ). 
Feasibility of home instillation will be assessed based on the totality of the data.  
Adverse Events  
The incidence of TEAEs (new or worsening from baseline) will be summarized by [CONTACT_113555] (PT), severity (based on CTCAE grades), type of AE, relation to 
study treatment. 
Deaths reportable as SAEs and non -fatal SAEs will be listed by [CONTACT_113556] . 
AESIs will be considered. A comprehensive list of reported AE terms based on clinical review 
will be used to identify Medical Dictionary for Regulatory Activities  (MedDRA) PTs for each of 
the AESI categories. For some events, several AE preferred terms may be ‘collapsed .’ The list of 
terms to be used for each category of adverse events of interest may be based on the Safety Review Team (SRT) agreements in place at the time of reporting. The SRT agreements are based 
on a review of the MedDRA dictionary. 
Summaries of the number and percentage of patients with these events will be provided for each 
type of events. Further details will be provided in the statistical analysis plan ( SAP). 
Clinical Laboratory Data 
Analyses of safety laboratory data will be performed for all collected laboratory parameters. 
Laboratory data will be graded according to CTCAE version  5.0 ( CTCAE, 2017), if applicable. 
In some cases (eg, white blood cell differentials), the lower limits of normal ranges used in CTCAE definition may need to be replaced by a clinically meaningful limit expressed in absolute counts. 
For laboratory tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory normal ranges. 
Data will be summarized and/or listed separately for hematology, biochemistry, and urinary 
laboratory tests as appropriate . 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126658] treatment visit and at the EOS Visit (or 
ET V isit). Details are provided in Section 1.[ADDRESS_126659] -baseline time points will be summarized. 
Patients exhibiting clinically notable vital sign abnormalities may be listed.  
10.4.3. Secondary Efficacy Endpoint(s)  
CR Rate at 3- month Visit (Disease Assessment)  
CR rate  is defined as the proportion of patients who achieved CR at the 3-m onth disease 
assessment  as determined  by [CONTACT_113511], for cause biopsy, and urine cytology. If a patient dies 
or terminates the study prior to the [ADDRESS_126660]  95% Clopper- Pearson CIs.  
10.4.4. Other Analysis  
Additional exploratory endpoints may be added in the SAP. 
10.5. Interim Analysis  
No interim analysis will be conducted. The final analysis will be performed after all patients 
complete the end of study visit or are withdrawn from the study.  
 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
51 11. Supporting Documentation and Operational Considerations   
11.1. Regulatory, Ethical, and Study Oversight Considerations 
11.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
• Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines 
• Applicable laws and regulations 
The protocol, protocol amendments, informed consent form (ICF), Investigator Brochure, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_42379]/IEC before the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study patients.  
Protocols and any substantial amendments to the protocol will require health authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study patients.  
The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC  
• Notifying the IRB/IEC of serious adverse events (SAEs) or other significant safety 
findings as required by [CONTACT_1744]/IEC procedures 
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), European Medical Device Regulation 2017/745 for clinical device 
research (if applicable), and all other applicable local regulations  
11.1.2. Finance and Insurance  
[IP_ADDRESS]. Finance  
The study is financed by [CONTACT_113557]/institution.  
[IP_ADDRESS]. Insurance 
The study will be covered in accordance with local requirements and per the clinical trial agreement.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
52 [IP_ADDRESS]. Consent and Other Informational Documents Provided to Patients  
Consent forms describing in detail the study treatment, study procedures, and risks are given to 
the patient, and written documentation of informed consent are required prior to initiating any 
study procedures and starting treatment/administering study treatment. The ICF is submitted with 
this protocol.  
The statement of informed consent must meet the requirements of [ADDRESS_126661] requirements, where 
applicable, and the IRB/IEC or study center. 
[IP_ADDRESS]. Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Consent forms will be 
IRB-approved, and the patient will be asked to read and review the document. The Investigator or his/her representative will explain the nature of the study to the patient or their legally 
authorized representative and answer all questions regarding the study. A verbal explanation will 
be provided in terms suited to the patient’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research patients. Patients will have the 
opportunity to carefully review the written consent form and ask questions prior to signing. The 
patients should have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate.  
Patients must be informed that their participation is voluntary and that they may withdraw from the study at any time, without prejudice. Patients or their legally authorized representative defined as per the applicable country -specific regulations will be required to sign a statement of 
informed consent prior to any procedures being done specifically for the study. 
The informed consent process will be conducted and documented in the source document 
(including the date), and the form signed, before the patient undergoes any study- specific 
procedures. The rights and welfare of the patients will be protected by [CONTACT_34693]. The authorized person obtaining the informed consent must also sign the ICF.  
Patients must be re -consented to the most current version of the ICF(s) during their participation 
in the study. 
A copy of the ICF(s) must be provided to the patient or their legally authorized representative.  
Patients who are re- screened are required to sign a new ICF.  
11.1.3. Data Protection, Confidentiality, and Privacy 
Patients will be assigned a unique identifier by [CONTACT_1034]. Any patient records or datasets that 
are transferred to the Sponsor should contain the identifier only; patient names or any 
information which would make the patient identifiable should not be transferred. 
The patient must be informed that his/her personal study -related data will be used by [CONTACT_35382]. The level of disclosure must also be explained to 
the patient who will be required, depending on the requirements of local law, to either 
acknowledge or agree that their data may be used as described in the informed consent.  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126662] be informed that his/her medical/pharmacy records and records may be 
examined by [CONTACT_13162], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. The 
clinical investigative site will permit access to such records.  
Patient confidentiality and privacy is strictly held in trust by [CONTACT_778], their 
staff, and the Sponsor and their interventions. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to patients.  
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No information concerning the study, or the data will be released to any 
unauthorized third party without prior written approval of the Sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study patient’s contact [CONTACT_62566]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], institutional policies, or Sponsor 
requirements.  
11.1.4. Data Review Committee  
No data review committee will be implemented for this study.
 
11.1.5. Dissemination of Clinical Study Data  
Data collected for this study will be analyzed and stored by [CONTACT_1034]. After the study is completed, the de-identified, archived data will be transmitted to and stored by [CONTACT_1034], for 
use by [CONTACT_21227]. Permission to transmit data to the Sponsor will be included in the informed consent.  
When the study is completed, access to study data and/or samples will be provided through the 
Sponsor. 
11.1.6. Safety Oversight 
Safety oversight will be under the direction of the Sponsor. Safety will be assessed throughout 
the course of the study by [CONTACT_113558]. 
11.1.7. Clinical Monitoring  
The Sponsor will perform on-site monitoring visits as frequently as necessary, depending on 
recruitment frequency at each site. The monitor will record dates of the visits in an investigative 
site visit log that will be kept at the site. Remote monitoring of patient Screening data will be performed on all patients, to ensure eligibility. The first post- initiation visit will be made as soon 
as possible (approximately 2-3 weeks) after enrollment has begun. At these visits, the monitor 
will compare the data entered i nto the eCRF with the hospi[INVESTIGATOR_40961] (source 
documents). The nature and location of all source documents will be identified to ensure that all 
sources of original data required to complete the eCRF are known to the Sponsor and 
investigational staff and are accessible for verification by [CONTACT_41067]. If electronic 
records are maintained at the investigational site, the method of verification must be discussed with the investigational staff.  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126663] access to source documentation (medical records) must be allowed for verifying that the 
data recorded in the eCRF are consistent with the original source data. Findings from this review 
of eCRFs and source documents will be discussed with the investigational staff. The Sponsor 
expects that, during monitoring visits, the relevant investigational staff will be available, the source documentation will be accessible, and a suitable environment will be provided for review 
of study-related documents. The monitor will meet with the Investigator on a regular basis during 
the study to provide feedback on the study conduct. Further details of clinical site monitoring including handling of noncompliance issues and monitoring techniques (central, remote, or on-
site monitoring) will be provided in a Study Monitoring Plan (SMP). The SMP will describe in 
detail who will conduct the monitoring, at what frequency monitoring will be done, at what level 
of detail monitoring will be performed, and the distribution of monitoring reports.  
Independent audits may be conducted by [CONTACT_18485]’s clinical quality assurance department or their designee to ensure that monitoring practices are performed consistently across all participating sites and that monitors are following the SMP.  
11.1.8. Data Quality Assurance 
All patient data relating to the study will be recorded on eCRF. The Investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_113559].  
Guidance on completion of eCRFs will be provided in the CRF Completion Guidelines. 
The Investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Quality tolerance limits (QTLs) or quality control (QC) checks identify systematic issues that 
can impact patient safety and/or reliability of study results. These QTLs or QC checks (ie, data 
QC checks) will be implemented for the EDC. Any missing data or data anomalies will be communicated to the sites for clarification/resolution.  
Following written Standard Operating Procedures, the monitors will verify that the clinical study is conducted, data are generated, and biological specimens are collected, documented (ie, recorded), and reported in compliance with the protocol, ICH GCP, and applicable regulatory 
requirements (eg, Good Laboratory Practices).  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data. 
The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract 
Research Organizations).  
Study patient research data, which are for purposes of statistical analysis and scientific reporting, 
will be transmitted to and stored by [CONTACT_1034]. This will not include the patient’s contact [CONTACT_10415]. Rather, individual patients and their research data will be identified by a unique study identification number. The study data entry and study management systems used by 
[CONTACT_113560]’s research staff will be secured and password -protected. At the 
end of the study, all study databases will be de-identified and archived by [CONTACT_1034]. 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126664] Keepi[INVESTIGATOR_007]  
[IP_ADDRESS]. Data Collection and Management Responsibilities  
This study will use an EDC system; the designated Investigator staff will enter the data required 
by [CONTACT_113561]. The eCRFs are built using fully validated, secure, web-enabled 
software that conforms to [ADDRESS_126665] been trained. Automatic validation programs check for 
data discrepancies in the eCRFs and allow modification or verification of the entered data by [CONTACT_113562].  
Data collection is the responsibility of the clinical study staff. The Investigator is responsible for 
ensuring the accuracy, completeness, legibility, and timeliness of the data reported. It is the Sponsor’s expectation that data required by [CONTACT_113563] a timely manner according to provided guidance. 
Clinical data will be entered directly from the source documents. All source documents should 
be completed in a neat, legible manner to ensure accurate interpretation of data and if applicable, 
signed or initialed and dated. 
Hard copi[INVESTIGATOR_113505]. Data recorded in the eCRF 
derived from source documents should be consistent with the data recorded on the source documents. 
Data collected at home health visits will be recorded by [CONTACT_113564].  
[IP_ADDRESS]. Study Records Retention  
Study documents should be retained for a minimum of [ADDRESS_126666] elapsed since the formal 
discontinuation of clinical development of the study treatment. These documents should be 
retained for a longer period, however, if required by [CONTACT_113565]. No 
records will be destroyed during the retention period without the written consent of the Sponsor, 
if applicable. It is the responsibility of the Sponsor to inform the Investigator when these documents no longer need to be retained. No records may be transferred to another location or 
party without written notification to the Sponsor. 
11.1.10. Protocol Deviations  
A protocol deviation is a departure from the study protocol and/or study related documents. The 
departure may be either on the part of the site or the patient and identified as site or patient 
deviations. As a result of deviations, corrective actions are to be developed by [CONTACT_90478].  
Protocol deviations related to study inclusion or exclusion criteria, conduct of the study, patient 
management or patient assessment should be addressed in study source documents and reported 
to the Sponsor. Protocol deviations must be submitted to the local or central IRB/IEC according to their guidelines. The site PI/study staff is responsible for knowing and adhering to their 
IRB/IEC requirements.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
56 11.1.11. Source Documents  
Source documents provide evidence for the existence of the patient and substantiate the integrity 
of the data collected. Source documents are filed at the Investigator’s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical 
records must be available.  
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF. 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. 
11.1.12. Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
patients.  
The first act of recruitment is the first site open and will be the study start date.  
Study/Site Termination  
The Sponsor or designee reserves the right to close the investigati ve site or terminate the study at 
any time for any reason at the sole discretion of the Sponsor. Investigati ve sites will be closed 
upon study completion. An investigative site is considered closed when all required documents and study supplies have been collected and an investigat ive site closure visit has been performed.  
The Investigator may initiate investigative site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of an investigative  site by [CONTACT_31202]:  
For study termination: 
• Discontinuation of further study treatment development  
• Determination of unexpected, significant, or unacceptable risk to patients 
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Determination that the primary endpoint has been met 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
57 For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants 
by [CONTACT_737] 
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigators, the IRBs/IECs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_13179]. The Investigator shall promptly inform the patient and should assure appropriate patient therapy and/or follow -up. 
The study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy the Sponsor, IRB, and/or FDA. 
11.1.13. Publication Policy  
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments. 
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a coordinating Investigator [INVESTIGATOR_12992]. 
Authorship will be determined by [CONTACT_27495]. 
11.1.14. Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by [CONTACT_81477], is critical. Therefore, any actual conflict of interest of persons who have 
a role in the design, conduct, analysis, publication, or any aspect of this study will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to 
have such conflicts managed in a way that is appropriate to their participation in the design and 
conduct of this study. The Sponsor has established policies and procedures for all study group members to disclose all conflicts of interest and will establish a mechanism for the management 
of all reported dualities of interest.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
58 12. References  
American Cancer Society (ACS). Cancer Facts & Figures 2020. Atlanta, GA, [LOCATION_003]: American 
Cancer Society; 2020. 
Avallone MA, Sack BS, El- Arabi A, et al. Ten -year review of perioperative complications after 
transurethral resection of bladder tumors: analysis of monopolar and plasmakinetic bipolar cases. 
J Endourol. 2017;31(8):767-773. 
Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-
muscle- invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 
2019;76(5):639-657. 
Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koç A, Akbulut Z. The actual incidence of 
bladder perforation following transurethral bladder surgery. J Urol. 2005;174(6):2260-2263. 
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder 
cancer: AUA/SUO guideline. J Urol. 2016;196:1021. 
Colombo R, Rocchini L, Suardi N, et al. Neoadjuvant short- term intensive intravesical 
mitomycin C regimen compared with weekly schedule for low -grade recurrent non- muscle-
invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol. 
2012;62(5):797-802. 
Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. US Department of 
Health and Human Services, National Institutes of Health, National Cancer Institute. 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_8.5x11.pdf. Published November 27, 2017. Accessed July 23, 2020. 
Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS -CoV- 2: A 
Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783-791.  
Daneshmand S, Patel S, Lotan Y, et al. Efficacy and safety of blue light flexible cystoscopy with 
hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter 
study. J Urol. 2018;199(5):1158-1165. 
De Nunzio C, Franco G, Cindolo L, et al. Transuretral resection of the bladder (TURB): analysis 
of complications using a modified Clavien system in an Italian real life cohort. Eur J Surg Oncol. 
2014;40(1):90-95. 
Erikson MS, Petersen AC, Andersen KK, Jacobsen FK, Mogensen K, Hermann GG. Do repeated 
transurethral procedures under general anesthesia influence mortality in patients with non -invasive 
urothelial bladder cancer? A Danish national cohort study. Scand J Urol. 2020;54(4):281-289. 
Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 
2015;7:65-79. Published 2015 May 4. 
Ghali F, Moses RA, Raffin E, Hyams ES. What factors are associated with unplanned return 
following transurethral resection of bladder tumor? An analysis of a large single institution's 
experience. Scand J Urol. 2016;50(5):370-373. 
Handley NR, Bekelman JE. The Oncology Hospi[INVESTIGATOR_113506]. J Clin Oncol. 2019;37(6):448-452.  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
59 Handley NR, Bekelman JE, Binder AF. The Home is the New Cancer Center.  J Natl Compr Canc 
Netw. 2020;18(10):1297-1299.  
Hollenbeck BK, Miller DC, Taub D, et al. Risk factors for adverse outcomes after transurethral 
resection of bladder tumors. Cancer. 2006;106(7):1527-1535. 
Huang W, Trainer A, Saltzstein D, Friedman B, Morris D. Can TURBT be avoided? Primary 
chemoablation with a reverse thermal gel containing mitomycin (UGN-102) in patients with low 
grade intermediate risk non -muscle invasive bladder cancer. J Urol.V. 203, No. 4S, Supplement, 
2020 (OPTIMA II) ([STUDY_ID_REMOVED]). 
Hurle R, Lazzeri M, Vanni E, et al. Active Surveillance for Low Risk Nonmuscle Invasive 
Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. J 
Urol. 2018;199(2):401-406. 
Innominato PF, Komarzynski S, Mohammad- Djafari A, et al. Clinical Relevance of the First 
Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer 
Patients at Home: The inCASA European Project.  J Med Internet Res. 2016;18(11):e305.  
Kamat AM, Witjes JA, Brausi M, et al. Defining and treating the spectrum of intermediate risk 
nonmuscle invasive bladder cancer. J Urol. 2014;192(2):305-315. 
Lal R, Bourayou N, Hillerdal G, et al. Home administration of maintenance pemetrexed for 
patients with advanced non-squamous non- small cell lung cancer: rationale, practicalities and 
phase II feasibility study design. Health Qual Life Outcomes. 2013;11:163.  
Laughlin AI, Begley M, Delaney T, et al. Accelerating the Delivery of Cancer Care at Home 
During the Covid-19 Pandemic. NEJM (Catalyst). 2020; Commentary.  
Lindgren MS, Bue P, Azawi N, et al. The DaBlaCa-13 Study: short- term, intensive 
chemoresection versus standard adjuvant intravesical instillations in non- muscle-invasive 
bladder cancer -a randomised controlled trial [published online ahead of print, 28 Jul 2020]. 
Eur Urol. 2020;S0302-2838(20)[ZIP_CODE]-8. 
Luthi F, Fucina N, Divorne N, et al. Home care --a safe and attractive alternative to inpatient 
administration of intensive chemotherapi[INVESTIGATOR_014].  Support Care Cancer. 2012;20(3):575-581.  
Marcq G, Hénon F, Ouzaid I, Fantoni JC, Hermieu JF, Xylinas E. Active surveillance for non-
muscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):54-60.  
Matulewicz RS, Sharma V, McGuire BB, Oberlin DT, Perry KT, Nadler RB. The effect of 
surgical duration of transurethral resection of bladder tumors on postoperative complications: 
an analysis of ACS NSQIP data. Urol Oncol. 2015;33(8):338.e19-24. 
Miyake M, Fujimoto K, Hirao Y. Active surveillance for nonmuscle invasive bladder cancer. 
Investig Clin Urol. 2016;57(Suppl 1):S4-S13. 
Monteiro LL, Witjes JA, Agarwal PK, et al. ICUD -SIU International Consultation on Bladder 
Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019;37(1):51-60. 
Mostafid AH, Porta N, Cresswell J, et al. CALIBER: a phase II randomized feasibility trial of 
chemoablation with mitomycin -C vs. surgical management in low-risk non- muscle -invasive 
bladder cancer. BJU Int. 2020;125(6):817-826. 
CONFIDENTIAL  Protocol BL010 version 1.0 
 
60 National Comprehensive Cancer Network (NCCN). Bladder Cancer (Version 6.2020). 
https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Updated July 16, 2020. 
Accessed August 25, 2020. 
Patel HD, Ball MW, Cohen JE, Kates M, Pi[INVESTIGATOR_113507], Allaf ME. Morbidity of urologic surgical 
procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85(3):552-559. 
Pereira JF, Pareek G, Mueller -Leonhard C, et al. The perioperative morbidity of transurethral 
resection of bladder tumor: implications for quality improvement. Urology. 2019;125:131-137. 
Rambachan A, Matulewicz RS, Pi[INVESTIGATOR_113508] M, Kim JY, Kundu SD. Predictors of readmission 
following outpatient urological surgery. J Urol. 2014;192(1):183-188. 
Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) Program ( www. seer.cancer.gov ) 
SEER*Stat Database: Incidence - SEER 21 Regs Research Data, Limited Field Research Data + 
Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (2000- 2016) <Katrina/Rita 
Population Adjustment> - Linked To County Attributes - Total U.S., 1969-[ADDRESS_126667] MS. Active surveillance for low-risk bladder cancer. Urol Oncol. 
2014;32:33.e7–33.e10.  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126668] be completed at each home instillation visit after the instillation is completed  
  Not at all  A little  Quite 
a bit Very much  
 Comfort      
1. Were you more comfortable with today’s instillation 
at home than at your doctor’s office?      
2. Did you find it more difficult receiving today’s 
instillation at home than at your doctor’s office?     
 Please explain (free text):  
3. Did the courtesy and caregiving of the home health 
professional make you feel comfortable?     
 Safety     
4. Did you have any concerns receiving the instillation 
at home, away from the doctor’s office?      
 Please explain (free text):  
 Communication     
5. Did you receive clear and sufficient instructions on what to do and what to expect before the instillation?      
6. Did you receive clear and sufficient instructions on 
what to do and what to expect after the instillation?     
 Preference      
7. Did you prefer to have today’s instillation done at 
home compared to the doctor’s office?      
 Please explain (free text):  
 Overall experience      
8. Overall are you satisfied with today’s instillation performed at home?      
 Please explain (free text):  
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126669] be completed at  the 3- month Visit (E nd of Study) or Early Termination Visit 
The purpose of this questionnaire is for you to share your recommendation based on your 
experience on this study. 
1. Will you recommend home instillations of UGN -102 for other patients with non- muscle -
invasive bladder cancer ( NMIBC)? 
• Yes 
• No 
Please explain (free text):  
2. Will you recommend home instillations of UGN -102 instead of having transurethral 
resection of bladder tumors (TURBT ) for other patients with  NMIBC?  
• Yes 
• No 
• Not applicable 
Please explain (free text):  
CONFIDENTIAL  Protocol BL010 version 1.0 
 
63 Appendix B.  Home Health Professional Questionnaire  
The purpose of this questionnaire is for you to share your experience on how you felt 
administering  UGN- 102 intravesical instillation at the patient’s home. Please indicate the extent 
to which you felt comfortable and safe with the treatment at the patient’s home and fill in the 
questionnaire as per your experience. 
Part [ADDRESS_126670] be completed at each home instillation visit after the instillation is completed  
1. Were you comfortable performing the instillation at this patient’s home?  
• Yes 
• No 
Please explain (free text):  
2. Was it difficult to perform the instillation at this patient’s home?  
• Yes 
• No 
Please explain (free text):  
3. Did you have any concerns performing the instillation in the home setting?  
• Yes 
• No 
Please explain (free text):  
4. Did you have sufficient support performing the instillation in the home setting? 
• Yes 
• No 
Please explain (free text):  
Part [ADDRESS_126671] be completed starting at the second  home instillation  visit ( Treatment 
Visit 3 onwards ) 
1. Did you perform the previous home instillation for this patient?  
• Yes 
• No 
 
CONFIDENTIAL  Protocol BL010 version 1.[ADDRESS_126672] be completed at  the 3- month Visit (E nd of Study) or Early Termination Visit 
The purpose of this questionnaire is to understand how comfortable and safe patients and home 
health professionals considered home instillation of UGN- 102. Please answer the questions below. 
1. Was the experience of having your patient receive instillations at home more difficult , 
less
 difficult, or not different than having them receive instillation in your office?  
• More difficult  
• Less difficult  
• Not different 
Please explain (free text):  
2. How can we improve the overall experience (free text)?  